

Unlocking geminal fluorohaloalkanes in nucleophilic fluoroalkylation chemistry: generation and trapping of lithiumfluorocarbenoids enabled by flow microreactors

Mauro Spennacchio,^{a,†} Marco Colella,^{a,†} Michael Andresini,^a Roberta Savina Dibenedetto,^a Elena Graziano,^a Andrea Aramini,^b Leonardo Degennaro,^{*a} and Renzo Luisi^{*,a}

^a FLAME-Lab, Flow Chemistry and Microreactor Technology Laboratory, Department of Pharmacy – Drug Sciences, University of Bari “A. Moro” Via E. Orabona 4 - 70125 Bari, Italy.

^b Department of Discovery, Dompé Farmaceutici S.p.A., Via Campo di Pile, L’Aquila 67100, Italy.

e-mail: renzo.luisi@uniba.it

Supporting Information

Table of contents:

1. [Instrumentation and General Methods](#)
2. [Batch procedures](#)
3. [General procedures for the continuous-flow nucleophilic fluoroalkylation](#)
4. [Characterization of compounds **3aa-3ck**](#)
5. [Copy of ¹H, ¹³C and ¹⁹F NMR spectra for compounds **3aa-3ck**](#)
6. [References](#)

1. Instrumentation and General methods

Infrared spectra were recorded in reciprocal centimeters (cm^{-1}) by using a PerkinElmer 283 spectrometer. Melting points (uncorrected) were measured with Büchi melting point B-545. ^1H , ^{13}C and ^{19}F NMR spectra were recorded with a Varian Mercury 300 spectrometer (300 MHz for ^1H , 75 MHz for ^{13}C , 282 MHz for ^{19}F) and an Agilent 500 spectrometer (500 MHz for ^1H , 126 MHz for ^{13}C , 470 MHz for ^{19}F). The residual solvent signal was used as an internal standard which was related to TMS with δ 7.26 ppm (^1H in CDCl_3), δ 77.00 ppm (^{13}C in CDCl_3). Spin-spin coupling constants (J) are given in Hz. When possible, unambiguous assignment of all resonances was performed by combined application of 2D NMR techniques, *i.e.* HSQC and COSY experiments. Data are reported as follows: chemical shift [multiplicity (s = singlet, d = doublet, t = triplet, q = quartet, p = quintet, m = multiplet and bs = broad signal), coupling constant (in Hz), integration and assignment]. NOESY experiments were performed for structure elucidation. High resolution mass spectrometry (HRMS) spectra were performed on Agilent 6530 accurate mass Q-TOF instrument and Excalibur data system. Diastereomeric ratios were assessed by ^1H NMR analysis on the reaction crude. Silica (70–230 mesh and 230–400 mesh) was used for flash chromatography on glass columns. TLC analysis were performed on a 0.25 mm precoated silica gel thick plates (Merck) with a fluorescence indicator F-254; the spots were visualized under UV light ($\lambda = 254$ nm) and/or KMnO_4 (aq.) was used as revealing system.

Chemicals were purchased from Sigma-Aldrich, Fluorochem, TCI Europe and Alfa Aesar unless otherwise specified and used without further purification. THF was distilled prior to use. Organolithium reagents were titrated prior to use (using *N*-benzylbenzamide as titrating agent).¹

Flow equipment: Stainless steel (SUS304) T-shaped micromixers with inner diameters of 250 μm were manufactured by Sanko Seiki Co., Inc. Stainless steel (SUS316) microtube reactors with inner diameter of 1000 μm purchased from GL Sciences were used unless otherwise stated. The micromixers and microtube reactors were connected with stainless steel fittings (GL Sciences, 1/16 OUV). A cryogenic bath was used to control the temperature. Solutions of reagents were fluxed using syringe pumps Harvard PHD 2000, equipped with gastight syringes purchased from SGE.

1.1 Picture of the continuous flow microreactor system




Figure S1. Continuous flow system.

Fluoroiodoalkanes were reacted with *n*-BuLi using T-shaped micromixer M₁ and microtube reactor R₁. The resulting solutions were reacted with electrophile in T-shaped micromixer M₂ and microtube reactor R₂. The flow microreactor system was dipped in a cooling bath to control the reaction temperature. Precooling units were used.

2. Batch procedures

2.1 Preparation of substrates

Substrates **1a-c** were prepared adopting reported procedures.^{2,3} Spectroscopic data are consistent with those reported in the literature.^{2,4,5}




Figure S2. Substrates **1a-c**.

2.1 Electrophiles collection

The following compounds are available from Sigma-Aldrich, TCI Europe, Fluorochem and Alfa Aesar except for electrophile **2v**, which was prepared adopting a reported procedure.⁶ Spectroscopic data are consistent with those reported in the literature.





Figure S3. Collection of electrophiles used in this work.

2.2 Table S1. Screening of solvents and organolithiums under internal quenching regime



To a stirred solution of **(2-fluoro-2-iodoethyl)benzene (1a)** (50 mg, 0.2 mmol) and **benzophenone (2a)** (36 mg, 0.2 mmol, 1 equiv.) at -78°C , in **solvent** (2 mL), the organolithium solution (**R-Li**) was added dropwise. The resulting mixture was stirred for 15 min at -78°C and then quenched with 150 μL of methanol. The crude was washed with distilled water (2 x 2 mL) and the aqueous layers were extracted with ethyl acetate (3 x 5 mL). The combined organic phases were dried over Na_2SO_4 , filtered, and concentrated under reduced pressure. Yields of **3aa** were evaluated using CH_2Br_2 as an NMR-internal standard.

Entry	Solvent	R-Li	Yield(%) of 3aa
1	THF-Et ₂ O 1:1 (v/v)	MeLi	75%
2	Toluene	MeLi	0%
3	CPME	MeLi	0%
4	Et ₂ O	MeLi	4%
5	2-MeTHF	MeLi	81%
6	THF	MeLi	90%
7	THF	n-BuLi	54%
8	THF	n-HexLi	50%

Table S1

2.3 Reactivity of 1a-Li, (1-fluoro-2-phenylethyl)lithium

To a stirred solution of **(2-fluoro-2-iodoethyl)benzene (1a)** (50 mg, 0.2 mmol) at -78°C , in THF (2 mL), **n-BuLi** (1.2 eq.) was added dropwise. The resulting mixture was stirred for 10 min at -78°C and then 5 min at room temperature. The volatiles were evaporated, and the crude was analyzed by ^1H , ^{19}F -NMR and GC-MS.





Figure S4. ^1H -NMR spectrum of the crude



Reported data for (E)-1,4-diphenylbut-2-ene. ^1H NMR (500 MHz, CDCl_3) δ 7.33 (t, $J = 9.0$ Hz, 4H), 7.24 (m, 6H), 5.75-6.68 (m, 2H), 3.42 (d, $J = 5.0$ Hz, 4H).⁷

Reported data for (Z)-1,4-diphenylbut-2-ene. ^1H NMR (500 MHz, CDCl_3) r (400 MHz, CDCl_3) δ (ppm) 7.39-7.20 (m, 10H), 5.87-5.63 (m, 2H), 3.56 (d, $J = 5.1$ Hz, 4H).⁸






Figure S5. ^{19}F -NMR spectrum of the crude




4a; (Z)-(2-fluorovinyl)benzene

^{19}F NMR (470 MHz, CDCl_3) δ -122.9 (ddd, $^2J_{(\text{H-F})} = 83.2$ Hz, $^3J_{(\text{H-F})} = 45.1, 2.7$ Hz, 1F, CHF). Spectroscopic data consistent with literature.⁹



4b; (E)-(2-fluorovinyl)benzene

^{19}F NMR (470 MHz, CDCl_3) δ -130.7 (ddd, $^2J_{(\text{H-F})} = 83.1$ Hz, $^3J_{(\text{H-F})} = 19.4, 3.3$ Hz, 1F, CHF). Spectroscopic data consistent with literature.¹⁰



5; 2-fluoroethylbenzene


^{19}F NMR (470 MHz, CDCl_3) δ -216.1 – -215.8 (m, 1F, CH_2F). Spectroscopic data consistent with literature.¹¹

2.4 General procedure for the “batch” monofluoroalkylation

To a stirred solution of **fluoroiodoalkane (1)** (0.3 mmol) and **electrophile (2)** (0.3 mmol, 1 equiv.) at -78°C , in **solvent** (3 mL), the *n*-butyllithium solution (***n*-BuLi**) (0.36 mmol, 1.2 equiv) was added dropwise. The resulting mixture was stirred for 15 min at -78°C and then quenched with 150 μL of methanol. The crude was washed with distilled water (2 x 2 mL) and the aqueous layers were extracted with ethyl acetate (3 x 5 mL). The combined organic phases were dried over Na_2SO_4 , filtered, and concentrated under reduced pressure. Yields of products **3** were evaluated using CH_2Br_2 as an NMR-internal standard.

3. General procedures for the continuous-flow nucleophilic fluoroalkylation

3.1 General procedure for lithiation of (2-fluoro-2-iodoethyl)benzene (1a) and trapping with benzophenone



using a flow microreactor system.

A microfluidic system consisting of two T-shaped micromixers (**M₁** and **M₂**), two microtube reactors (**R₁** and **R₂**), and three tube precooling units was used. The microfluidic system was cooled with a cooling bath ($T^{\circ}\text{C}$). A solution of **(2-fluoro-2-iodoethyl)benzene (1a)** (0.10 M in THF) (flow rate: 4.0 mL/min) and a solution of *n*-BuLi (0.20 M in hexane, 2 equiv.) (flow rate: 4.0 mL/min) were introduced to **M₁** ($\phi = 500\ \mu\text{m}$) by syringe pumps. The resulting solution was passed through **R₁** and was mixed with a solution of **benzophenone (2a)** (0.30 M in THF, 3 equiv.) (flow rate: 4.0 mL/min) in **M₂** ($\phi = 500\ \mu\text{m}$). The resulting solution was passed through **R₂** ($\phi = 1000\ \mu\text{m}$, $L = 200\ \text{cm}$; $t^{\text{R}2} = 7.85\ \text{s}$). After reaching the steady state, the outcoming solution was collected for 1 minute in a vessel containing 2 mL of distilled water. The yield of **3aa** was determined by GC analysis using decane as the internal standard. The results obtained by screening the residence time and the temperature are summarized in the following table and 3D-maps.

Table S2. Evaluation of residence time and temperature effects on yield.

Entry	T (°C)	ϕ_1	L ₁	t ^{R1} (ms)	Yield (%)
1	0°C	250 μm	3.5cm	13ms	0%
2	-30°C	250 μm	3.5cm	13ms	36%
3	-30°C	500 μm	3.5cm	52ms	30%
4	-30°C	750 μm	3.5cm	116ms	26%
5	-30°C	1000 μm	3.5cm	206ms	17%
6	-30°C	1000 μm	6cm	353ms	13%
7	-50°C	250 μm	3.5cm	13ms	79%
8	-50°C	500 μm	3.5cm	52ms	63%
9	-50°C	750 μm	3.5cm	116ms	58%

10	-50°C	1000µm	3.5cm	206ms	57%
11	-50°C	1000µm	6cm	353ms	48%
12	-78°C	250µm	3.5cm	13ms	68%
13	-78°C	500µm	3.5cm	52ms	63%
14	-78°C	750µm	3.5cm	116ms	53%
15	-78°C	1000µm	3.5cm	206ms	80%
16	-78°C	1000µm	6cm	353ms	38%
17	-78°C	1000µm	12.5cm	736ms	24%





Figure S6. 3-D map.

3.2 Evaluation of the transition between internal and external regime



Entry 1 and 2: A microfluidic system consisting of two T-shaped micromixers (M_1 and M_2), two microtube reactors (R_1 and R_2), and three tube precooling units was used. The microfluidic system was cooled with a cooling bath (Entry 1: $T = -50^\circ\text{C}$; Entry 2: $T = -78^\circ\text{C}$). A solution of (2-fluoro-2-iodoethyl)benzene (**1a**) (0.10 M in THF) (flow rate: 4.0 mL/min) and a solution of *n*-BuLi (0.20 M in hexane, 2 equiv.) (flow rate: 4.0 mL/min) were introduced to M_1 ($\phi = 500\ \mu\text{m}$) by syringe pumps. The resulting solution was passed through R_1 (Entry 1: $\phi = 250\ \mu\text{m}$, $L = 3.5\ \text{cm}$, $t^{R1} = 13\ \text{ms}$; Entry 2: $\phi = 1000\ \mu\text{m}$, $L = 3.5\ \text{cm}$, $t^{R1} = 206\ \text{ms}$) and was mixed

with a solution of *N*-methyl-*N*-methoxybenzamide (**2t**) (0.30 M in THF, 3 equiv.) (flow rate: 4.0 mL/min) in **M**₂ ($\phi = 500 \mu\text{m}$). The resulting solution was passed through **R**₂ ($\phi = 1000 \mu\text{m}$, $L = 200 \text{ cm}$; $t^{\text{R}2} = 7.85 \text{ s}$) at -78°C . After a steady state was reached, the outcoming solution was collected for 1 minute in a vessel containing 2 mL of distilled water. The yield of **3ab** was determined using CH_2Br_2 as an NMR-internal standard.


Entry 3: A microfluidic system consisting of one T-shaped micromixer (**M**₁), one microtube reactor (**R**₁), and two tube precooling units was used. The microfluidic system was cooled to -78°C with a cooling bath (T °C). A solution of (2-fluoro-2-iodoethyl)benzene (**1a**) (0.10 M in THF) and *N*-methyl-*N*-methoxybenzamide (**2t**) (0.30 M in THF, 3 equiv.) (flow rate: 4.0 mL/min) and a solution of *n*-BuLi (0.20 M in hexane, 2 equiv.) (flow rate: 4.0 mL/min) were introduced to **M**₁ ($\phi = 500 \mu\text{m}$) by syringe pumps. The resulting solution was passed through **R**₁ ($\phi = 1000 \mu\text{m}$, $L = 200 \text{ cm}$, $t^{\text{R}1} = 5.23 \text{ s}$) (flow rate: 4.0 mL/min). After a steady state was reached, the outcoming solution was collected for 1 minute in a vessel containing 2 mL of distilled water. The yield of **3ab** was determined using CH_2Br_2 as an NMR-internal standard.

Table S3. Evaluation of the transition between internal and external regime.

Entry	T (°C)	ϕ_1	L_1	$t^{\text{R}1}(\text{ms})$	Yield (%)
1	-50°C	250 μm	3.5cm	13ms	43%
2	-78°C	1000 μm	3.5cm	206ms	71%
3	-78°C	1000 μm	200cm	5.23s	30%


These results suggest that the trapping of the reactive intermediate after 206ms at -78°C occurs under an external quenching regime.

3.3 General procedure (GP) for the continuous flow nucleophilic-monofluoroalkylation




A microfluidic system consisting of two T-shaped micromixers (**M**₁ and **M**₂), two microtube reactors (**R**₁ and **R**₂), and three tube precooling units was used. The microfluidic system was cooled to -78°C with a cooling bath. A solution of 1-fluoro-1-iodoalkane (**1a-c**) (0.35 M in THF, 2.3 equiv.) (flow rate: 4.0 mL/min) and a solution of *n*-BuLi (0.15 M in hexane, 1 equiv.) (flow rate: 4.0 mL/min) were introduced to **M**₁ ($\phi = 500 \mu\text{m}$) by syringe pumps. The resulting solution was passed through **R**₁ ($\phi = 1000 \mu\text{m}$, $L = 3.5 \text{ cm}$, $t^{\text{R}1} = 206 \text{ ms}$) and was mixed with a solution of electrophile (**2a-x**) (0.15 M in THF, 1 equiv.) (flow rate: 4.0 mL/min) in **M**₂ ($\phi = 500 \mu\text{m}$). The resulting solution was passed through **R**₂ ($\phi = 1000 \mu\text{m}$, $L = 200 \text{ cm}$; $t^{\text{R}2} = 7.85 \text{ s}$). After reaching the steady state, the outcoming solution was collected for 1 minute in a vessel containing 2 mL of distilled water. The aqueous and the organic phase were separated, and the aqueous layer was extracted with Et_2O ($3 \times 2 \text{ mL}$). The combined organic layers were dried over Na_2SO_4 , concentrated, and the crude was purified through flash column chromatography, affording the desired product. Purification allowed the recovery of the residual 1-fluoro-1-iodoalkane (up to 70%), which was re-used. Stereochemistry of the products was not assigned.

4. Characterization of compounds 3aa-3ck




3aa; 2-fluoro-1,1,3-triphenylpropan-1-ol

Prepared according to general procedure GP to afford **3aa** as a white waxy solid (174 mg, 95%) after column chromatography ($R_f=0.3$, hexane/Et₂O 9:1); IR (film)/cm⁻¹ 3436, 3089, 2935, 1954, 1638, 1495, 1449, 1274; ¹H NMR (500 MHz, CDCl₃) δ 7.56 (d, $J=8.1$ Hz, 2H, 2 \times Ar-H), 7.46 (d, $J=7.4$ Hz, 2H, 2 \times Ar-H), 7.34 (t, $J=7.6$ Hz, 4H, 4 \times Ar-H), 7.30–7.21 (m, 5H, 5 \times Ar-H, overlapping with CDCl₃), 7.15 (d, $J=7.4$ Hz, 2H, 2 \times Ar-H), 5.57 (ddd, $^2J_{(H-F)}=47.1$ Hz, $^3J_{(H-H)}=10.0$, 1.6 Hz, 1H, CHFCH₂), 3.08–2.99 (m, 1H, PhCHHCHF), 2.72 (d, $^4J_{(H-F)}=1.7$, 1H, O-H), 2.68 (ddd, $^3J_{(H-F)}=42.0$ Hz, $^2J_{(H-H)}=14.9$, $^3J_{(H-H)}=1.6$ Hz, 1H, PhCHHCHF); ¹³C NMR (125 MHz, CDCl₃) δ 144.5 (Ar-C_q), 143.1 (d, $^3J_{(C-F)}=4.1$ Hz, Ar-C_q), 138.3 (Ar-C_q), 129.3 (2 \times Ar-C), 129.4 (2 \times Ar-C), 128.6 (2 \times Ar-C), 128.5 (2 \times Ar-C), 128.4 (2 \times Ar-C), 127.6 (Ar-C), 127.5 (Ar-C), 126.9 (d, $^4J_{(C-F)}=1.7$ Hz, 2 \times Ar-C), 126.6 (Ar-C), 97.0 (d, $^1J_{(C-F)}=181.5$ Hz, CHF), 79.4 (d, $^2J_{(C-F)}=20.7$ Hz, C_qOHCHF), 35.8 (d, $^2J_{(C-F)}=21.4$ Hz, PhCH₂CHF); ¹⁹F NMR (470 MHz, CDCl₃) δ -187.4 (ddd, $^2J_{(H-F)}=47.1$ Hz, $^3J_{(H-F)}=42.0$, 16.6 Hz, 1F, CHF); HRMS (ESI) m/z Calcd for C₂₁H₁₈FO [M-H]⁻ 305.1347; Found: 305.1338.




3ab; 1,1-bis(4-chlorophenyl)-2-fluoro-3-phenylpropan-1-ol

Prepared according to general procedure GP to afford **3ab** as a white waxy solid (202 mg, 90%) after column chromatography ($R_f=0.3$, hexane/Et₂O 9:1); IR (film)/cm⁻¹ 3583, 3063, 2932, 1904, 1593, 1492, 1321, 823; ¹H NMR (500 MHz, CDCl₃) δ 7.46 (d, $J=8.6$ Hz, 2H, 2 \times Ar-H), 7.37–7.36 (m, 2H, 2 \times Ar-H), 7.33–7.28 (m, 6H, 6 \times Ar-H), 7.26–7.23 (m, 1H, Ar-H), 7.14 (d, $J=7.6$ Hz, 2H, 2 \times Ar-H), 5.47 (ddd, $^2J_{(H-F)}=47.0$ Hz, $^3J_{(H-H)}=9.9$, 1.7 Hz, 1H, CHFCH₂), 3.04–2.95 (m, 1H, PhCHHCHF), 2.73–2.60 (m, 2H, PhCHHCHF overlapping with O-H); ¹³C NMR (125 MHz, CDCl₃) δ 142.5 (Ar-C_q), 141.2 (d, $^3J_{(C-F)}=3.9$ Hz, Ar-C_q), 137.6 (Ar-C_q), 133.8 (d, $^3J_{(C-F)}=4.0$ Hz, Ar-C_q), 129.3 (2 \times Ar-C), 128.9 (2 \times Ar-C), 128.7 (2 \times Ar-C), 128.6 (2 \times Ar-C), 128.4 (2 \times Ar-C), 127.5 (2 \times Ar-C), 126.8 (Ar-C), 96.6 (d, $^1J_{(C-F)}=182.2$ Hz, CHF), 78.8 (d, $^2J_{(C-F)}=21.1$ Hz, C_qOHCHF), 35.7 (d, $^2J_{(C-F)}=21.3$ Hz, PhCH₂CHF); ¹⁹F NMR (470 MHz, CDCl₃) δ -186.8 (ddd, $^2J_{(H-F)}=47.0$ Hz, $^3J_{(H-F)}=41.9$, 16.6 Hz, 1F, CHF); HRMS (ESI) m/z Calcd for C₂₁H₁₆Cl₂FO [M-H]⁻ 373.0568; Found: 373.0546.




3ac; 2-fluoro-1,1-bis(4-fluorophenyl)-3-phenylpropan-1-ol

Prepared according to general procedure GP to afford **3ac** as a white waxy solid (195 mg, 95%) after column chromatography ($R_f = 0.4$, hexane/Et₂O 9:1); IR (film)/cm⁻¹ 3585, 3065, 2936, 1897, 1604, 1505, 1233, 835; ¹H NMR (500 MHz, CDCl₃) δ 7.51–7.48 (m, 2H, 2 \times Ar–H), 7.41–7.38 (m, 2H, 2 \times Ar–H), 7.30–7.22 (m, 3H, 3 \times Ar–H), 7.13 (d, $J = 7.3$ Hz, 2H, 2 \times Ar–H), 7.05–7.00 (m, 4H, 4 \times Ar–H), 5.47 (ddd, $^2J_{(H-F)} = 47.1$ Hz, $^3J_{(H-H)} = 9.9$, 1.8 Hz, 1H, CHFCH₂), 3.02–2.94 (m, 1H, PhCHHCHF), 2.72–2.60 (m, 2H, PhCHHCHF overlapping with O–H); ¹³C NMR (125 MHz, CDCl₃) δ 162.2 (d, $^1J_{(C-F)} = 246.9$ Hz, Ar–C_q), 162.1 (d, $^1J_{(C-F)} = 247.0$ Hz, Ar–C_q), 140.0 (d, $^3J_{(C-F)} = 3.3$ Hz, Ar–C_q), 138.9 (t, $^3J_{(C-F)}$ and $^4J_{(C-F)} = 3.5$ Hz, Ar–C_q), 137.8 (Ar–C_q), 129.3 (2 \times Ar–C), 128.2 (d, $^3J_{(C-F)} = 8.1$ Hz, $^4J_{(C-F)} = 2.0$ Hz, 2 \times Ar–C), 128.6 (2 \times Ar–C), 127.9 (d, $^3J_{(C-F)} = 8.1$ Hz, 2 \times Ar–C), 126.8 (Ar–C), 115.6 (d, $^2J_{(C-F)} = 21.4$ Hz, 2 \times Ar–C), 115.3 (d, $^2J_{(C-F)} = 21.3$ Hz, 2 \times Ar–C), 96.9 (d, $^1J_{(C-F)} = 182.1$ Hz, CHF), 78.7 (d, $^2J_{(C-F)} = 21.1$ Hz, C_qOHCHF), 35.7 (d, $^2J_{(C-F)} = 21.4$ Hz, PhCH₂CHF); ¹⁹F NMR (470 MHz, CDCl₃) δ -114.7–114.8 (m, 1F, Ar–F), 114.8–114.9 (m, 1F, Ar–F), -186.3 (ddd, $^2J_{(H-F)} = 47.1$ Hz, $^3J_{(H-F)} = 41.9$, 16.6 Hz, 1F, CHF); HRMS (ESI) m/z Calcd for C₂₁H₁₆F₃O [M–H]⁻ 341.1159; Found: 341.1177.



3ad; 1-(4-bromophenyl)-2-fluoro-1,3-diphenylpropan-1-ol

Prepared according to general procedure GP to afford **3ad** as a white waxy solid (dr = 50:50, 212 mg, 92%) after column chromatography ($R_f = 0.3$, hexane/Et₂O 9:1); *Inseparable mixture of diastereoisomers*; IR (film)/cm⁻¹ 3564, 3062, 2966, 1953, 1603, 1487, 1397, 1071; ¹H NMR (500 MHz, CDCl₃, *mixture of diastereoisomers*) δ 7.53–7.51 (m, 2H, 2 \times Ar–H), 7.47–7.45 (m, 4H, 4 \times Ar–H), 7.43–7.41 (m, 4H, 4 \times Ar–H), 7.36–7.32 (m, 6H, 6 \times Ar–H), 7.30–7.27 (m, 6H, 6 \times Ar–H), 7.25–7.21 (m, 2H, 2 \times Ar–H), 7.14 (d, $J = 7.3$ Hz, 4H, 4 \times Ar–H), 5.58–5.45 (m, 2H, 2 \times CHFCH₂), 3.08–2.94 (m, 2H, 2 \times PhCHHCHF), 2.74–2.59 (m, 4H, 2 \times PhCHHCHF overlapping with 2 \times O–H); ¹³C NMR (125 MHz, CDCl₃, *mixture of diastereoisomers*) δ 144.0 (Ar–C_q), 143.5 (Ar–C_q), 142.6 (d, $^3J_{(C-F)} = 3.9$ Hz, Ar–C_q), 142.2 (d, $^3J_{(C-F)} = 4.2$ Hz, Ar–C_q), 138.0 (Ar–C_q), 137.9 (Ar–C_q), 131.7 (2 \times Ar–C), 131.5 (2 \times Ar–C), 129.4 (4 \times Ar–C), 128.9 (Ar–C), 128.8 (3 \times Ar–C), 128.6 (4 \times Ar–C), 127.8 (6 \times Ar–C), 126.8 (2 \times Ar–C), 126.7 (2 \times Ar–C), 125.9 (2 \times Ar–C), 121.7 (2 \times Ar–C_q), 96.8 (d, $^1J_{(C-F)} = 181.7$ Hz, CHF), 96.6 (d, $^1J_{(C-F)} = 182.0$ Hz, CHF), 79.2 (d, $^2J_{(C-F)} = 21.1$ Hz, C_qOHCHF), 79.1 (d, $^2J_{(C-F)} = 20.9$ Hz, C_qOHCHF), 35.8 (d, $^2J_{(C-F)} = 21.2$ Hz, PhCH₂CHF), 35.7 (d, $^2J_{(C-F)} = 21.5$ Hz, PhCH₂CHF); ¹⁹F NMR (470 MHz, CDCl₃) δ -187.0 – -187.3 (m, 2F, 2 \times CHF); HRMS (ESI) m/z Calcd for C₂₁H₁₇BrFO [M–H]⁻ 383.0452; Found: 383.0448.




3ae; 1-(1-fluoro-2-phenylethyl)-3-methylcyclohex-2-en-1-ol

Prepared according to general procedure GP to afford **3ae** (dr = 80:20) obtained as a white waxy solid (dr = 71:29, 91 mg, 65%) after column chromatography ($R_f = 0.5$, hexane/Et₂O 7:3); *Inseparable mixture of diastereoisomers*; IR (film)/cm⁻¹ 3583, 3418, 3029, 2931, 1947, 1670, 1454, 1063; ¹H NMR (500 MHz, CDCl₃, mixture of diastereoisomers) δ 7.32–7.30 (m, 2H major + 0.8H minor, Ar–H), 7.27–7.22 (m, 3H major + 1.2H minor, Ar–H), 5.50 (s, 0.4H, CH), 5.42 (s, 1H, CH), 5.47–5.43 (m, 1H major + 0.4H minor, CHFCH₂), 3.05–2.86 (m, 2H major + 0.8H minor, 2 × PhCHHCHF), 2.03–1.93 (m, 3H major + 1.2H minor, CH₂ overlapping with O–H), 1.82–1.71 (m, 7H major + 2.8H minor, 2 × CH₂ overlapping with CH₃); ¹³C NMR (125 MHz, CDCl₃, mixture of diastereoisomers) δ 141.7 (d, ⁴J_(C-F) = 1.2 Hz Csp²CH₃), 141.3 (d, ⁴J_(C-F) = 1.6 Hz Csp²CH₃), 138.4 (Ar–C_q), 138.3 (Ar–C_q), 129.4 (2 × Ar–C), 129.3 (2 × Ar–C), 128.6 (2 × Ar–C), 128.5 (2 × Ar–C), 126.6 (Ar–C), 126.5 (Ar–C), 122.5 (d, ³J_(C-F) = 4.2 Hz Csp²COH), 122.1 (d, ³J_(C-F) = 6.4 Hz Csp²COH), 99.9 (d, ¹J_(C-F) = 177.6 Hz, CHF), 98.5 (d, ¹J_(C-F) = 178.5 Hz, CHF), 71.9 (d, ²J_(C-F) = 20.5 Hz, C_qOHCHF), 71.5 (d, ²J_(C-F) = 19.5 Hz, C_qOHCHF), 36.2 (d, ²J_(C-F) = 21.8 Hz, PhCH₂CHF), 35.8 (d, ²J_(C-F) = 21.7 Hz, PhCH₂CHF), 31.3 (d, ³J = 3.2 Hz, CH₂), 30.8 (d, ³J = 3.2 Hz, CH₂), 30.5 (CH₂), 30.3 (CH₂), 24.1 (2 × CH₃), 18.9 (CH₂), 18.6 (CH₂); ¹⁹F NMR (470 MHz, CDCl₃) δ -190.4 – -190.6 (m, 1F major, CHF), -193.6 (ddd, ²J_(H-F) = 47.9 Hz, ³J_(H-F) = 40.5, 18.2 Hz, 0.4F minor, CHF); HRMS (ESI) m/z Calcd for C₁₅H₁₉FNao [M+Na]⁺ 257.1312; Found: 257.1319.



3af; 1-(1-fluoro-2-phenylethyl)cyclohexan-1-ol


Prepared according to general procedure GP to afford **3af** as a colorless waxy solid (93 mg, 70%) after column chromatography ($R_f = 0.3$, hexane/EtOAc 9:1); IR (film)/cm⁻¹ 3565, 3428, 3029, 2933, 1945, 1454, 1269, 975; ¹H NMR (500 MHz, CDCl₃) δ 7.34–7.30 (m, 2H, 2 × Ar–H), 7.26–7.22 (m, 3H, 3 × Ar–H), 4.42 (ddd, ²J_(H-F) = 47.7 Hz, ³J_(H-H) = 8.3, 4.2 Hz, 1H, CHFCH₂), 3.00–2.89 (m, 2H, 2 × PhCHHCHF), 1.78–1.46 (m, 9H, 4 × CH₂ overlapping with O–H), 1.34–1.25 (m, 2H, CH₂); ¹³C NMR (125 MHz, CDCl₃) δ 138.4 (d, ³J_(C-F) = 1.1 Hz, Ar–C_q), 129.4 (2 × Ar–C), 128.6 (2 × Ar–C), 126.6 (Ar–C), 99.8 (d, ¹J_(C-F) = 175.5 Hz, CHF), 72.6 (d, ²J_(C-F) = 19.5 Hz, C_qOHCHF), 37.6 (CH₂), 35.5 (d, ²J_(C-F) = 21.9 Hz, PhCH₂CHF), 33.4 (d, ³J_(C-F) = 4.1 Hz, CH₂), 32.7 (d, ³J_(C-F) = 3.5 Hz, CH₂), 25.8 (2 × CH₂), 21.4 (2 × CH₂); ¹⁹F NMR (470 MHz, CDCl₃) δ -193.6– -193.8 (m, 1F, CHF); HRMS (ESI) m/z Calcd for C₁₄H₁₈FO [M-H]⁻ 221.1347; Found: 221.1351.



3ag; 3-fluoro-2,4-diphenylbutan-2-ol


Prepared according to general procedure GP to afford **3ag** as a colorless waxy solid (dr = 50:50, 110 mg, 75%) after column chromatography ($R_f = 0.4$, hexane/EtOAc 9:1); *Inseparable mixture of diastereoisomers*; IR (film)/cm⁻¹ 3565, 3433, 3029, 2978, 1953, 1447, 1069, 699; ¹H NMR (500 MHz, CDCl₃, mixture of diastereoisomers) δ 7.54 (d, $J = 7.4$ Hz, 2H, 2 × Ar–H), 7.50–7.48 (m, 2H, 2 × Ar–H), 7.40 (t, $J = 7.8$ Hz, 4H, 4 × Ar–H), 7.34–7.31 (m, 2H, 2 × Ar–H), 7.27–7.17 (m, 6H, 6 × Ar–H overlapping with CDCl₃), 7.14 (d, $J = 7.4$ Hz, 2H, 2 × Ar–H), 7.09 (d, $J = 7.3$ Hz, 2H, 2 × Ar–H), 4.82–4.70 (m, 2H, 2 × CHFCH₂), 2.87–2.67 (m, 3H, 3 × PhCHHCHF), 2.55 (ddd, ³J_(H-F) = 42.3 Hz, ²J_(H-H) = 15.2 Hz, ³J_(H-H) = 1.5 Hz, 1H, PhCHHCHF), 2.33 (s, 1H, O–H), 2.20 (s, 1H, O–H), 1.69 (s, 6H, 2 × CH₃); ¹³C NMR (125 MHz, CDCl₃, mixture of diastereoisomers) δ 143.6 (d, ³J_(C-F) = 4.5 Hz, Ar–C_q), 143.4 (d, ³J_(C-F) = 2.0 Hz, Ar–C_q), 138.3 (Ar–C_q), 137.9 (Ar–C_q), 129.2 (4 × Ar–C), 128.6 (4 × Ar–C), 128.5 (4 × Ar–C), 127.7 (Ar–C), 127.5 (Ar–C), 126.6 (Ar–C), 126.5 (Ar–C), 125.9 (2 × Ar–C), 125.1 (2 × Ar–C), 99.8 (d, ¹J_(C-F) = 180.2 Hz, CHF), 99.7 (d, ¹J_(C-F) = 180.4 Hz, CHF), 75.8 (d, ²J_(C-F) = 20.6 Hz, 2 × C_qOHCHF), 36.4 (d, ²J_(C-F) = 21.4 Hz, PhCH₂CHF), 35.7 (d, ²J_(C-F) = 21.6 Hz, PhCH₂CHF), 27.4 (d, ³J_(C-F) = 4.0 Hz, CH₃), 24.9 (d, ³J_(C-F) = 3.4

Hz, CH₃); ¹⁹F NMR (470 MHz, CDCl₃) δ -187.8 (ddd, ²J_(H-F) = 48.0 Hz, ³J_(H-F) = 41.7, 17.5 Hz, 1F, CHF), -191.7 (ddd, ²J_(H-F) = 46.2 Hz, ³J_(H-F) = 42.3, 17.0 Hz, 1F, CHF); HRMS (ESI) m/z Calcd for C₁₆H₁₆FO [M-H]⁻ 243.1191; Found: 243.1186.




3ah-major; 6-chloro-2-fluoro-3-(4-fluorophenyl)-1-phenylhexan-3-ol

Prepared according to general procedure GP to afford **3ah-major** as a white waxy solid (105 mg, 90%) after column chromatography (R_f = 0.4, hexane/Et₂O 8:2); IR (film)/cm⁻¹ 3430, 2919, 2850, 1645, 1510, 1225, 1094, 830; ¹H NMR (500 MHz, CDCl₃) δ 7.43–7.39 (m, 2H, 2 × Ar-H), 7.26 (t, J = 7.2 Hz, 2H, 2 × Ar-H, overlapping with CDCl₃), 7.22–7.19 (m, 1H, Ar-H), 7.12–7.08 (m, 2H, 2 × Ar-H), 7.06 (d, J = 7.2 Hz, 2H, 2 × Ar-H), 4.79 (ddd, ²J_(H-F) = 47.6 Hz, ³J_(H-H) = 10.0, 2.0 Hz, 1H, CHFCH₂), 3.48 (t, ³J_(H-H) = 6.5 Hz, 2H, CH₂Cl), 2.91 (ddd, ³J_(H-F) = 17.3 Hz, ²J_(H-H) = 15.2 Hz, ³J_(H-H) = 10.0 Hz, 1H, PhCHHCHF), 2.45 (ddd, ³J_(H-F) = 41.3 Hz, ²J_(H-H) = 15.2 Hz, ³J_(H-H) = 2.0 Hz, 1H, PhCHHCHF), 2.28–2.20 (m, 2H, CHHCOH overlapping with O-H), 2.11–2.05 (m, 1H, CHHCOH), 1.87–1.79 (m, 1H, CHHCH₂Cl), 1.49–1.41 (m, 1H, CHHCH₂Cl); ¹³C NMR (125 MHz, CDCl₃) δ 162.1 (d, ¹J_(C-F) = 246.5 Hz, Ar-C_q), 137.8 (Ar-C_q), 136.4 (dd, ³J_(C-F) = 4.8 Hz, ⁴J_(C-F) = 3.3 Hz, Ar-C_q), 129.2 (2 × Ar-C), 128.5 (2 × Ar-C), 127.3 (d, ³J_(C-F) = 8.0 Hz, 2 × Ar-C), 126.6 (Ar-C), 115.7 (d, ²J_(C-F) = 21.3 Hz, 2 × Ar-C), 99.8 (d, ¹J_(C-F) = 180.3 Hz, CHF), 77.8 (d, ²J_(C-F) = 19.7 Hz, C_qOHCHF), 45.4 (CH₂Cl), 36.7 (d, ³J_(C-F) = 3.4 Hz, CH₂COH), 35.5 (d, ²J_(C-F) = 21.7 Hz, PhCH₂CHF), 26.6 (CH₂CH₂Cl); ¹⁹F NMR (470 MHz, CDCl₃) δ -115.2 – -115.1 (m, 1F, Ar-F), -191.5 (ddd, ²J_(H-F) = 47.6 Hz, ³J_(H-F) = 41.3, 17.3 Hz, 1F, CHF); HRMS (ESI) m/z Calcd for C₁₈H₁₉Cl₂F₂ [M+Cl]⁻ 359.0787; Found: 359.0784.




3ah-minor; 6-chloro-2-fluoro-3-(4-fluorophenyl)-1-phenylhexan-3-ol

Prepared according to general procedure GP to afford **3ah-minor** as a white waxy solid (70 mg, 90%) after column chromatography (R_f = 0.3, hexane/Et₂O 8:2); IR (film)/cm⁻¹ 3434, 2918, 2850, 1645, 1506, 1455, 1226, 1063; ¹H NMR (500 MHz, CDCl₃) δ 7.50–7.47 (m, 2H, 2 × Ar-H), 7.29 (t, J = 7.3 Hz, 2H, 2 × Ar-H), 7.23 (t, J = 7.3 Hz, 1H, Ar-H), 7.15 (d, J = 7.4 Hz, 2H, 2 × Ar-H), 7.11–7.08 (m, 2H, 2 × Ar-H), 4.70 (ddd, ²J_(H-F) = 47.7 Hz, ³J_(H-H) = 10.0, 2.2 Hz, 1H, CHFCH₂), 3.55–3.52 (m, 2H, CH₂Cl), 2.90 (ddd, ³J_(H-F) = 41.4 Hz, ²J_(H-H) = 14.8 Hz, ³J_(H-H) = 2.2 Hz, 1H, PhCHHCHF), 2.67 (ddd, ³J_(H-F) = 16.8 Hz, ²J_(H-H) = 14.8 Hz, ³J_(H-H) = 10.0 Hz, 1H, PhCHHCHF), 2.30–2.24 (m, 1H, CHHCOH), 2.22 (d, ⁴J_(H-F) = 1.1 Hz, 1H, O-H), 2.08–2.02 (m, 1H, CHHCOH), 1.92–1.84 (m, 1H, CHHCH₂Cl), 1.63–1.54 (m, 1H, CHHCH₂Cl); ¹³C NMR (125 MHz, CDCl₃) δ 162.3 (d, ¹J_(C-F) = 246.4 Hz, Ar-C_q), 137.6 (d, ⁴J_(C-F) = 0.6 Hz, Ar-C_q), 136.9 (d, ³J_(C-F) = 3.2 Hz, Ar-C_q), 129.3 (2 × Ar-C), 128.6 (2 × Ar-C), 128.1 (dd, ³J_(C-F) = 8.0 Hz, ⁴J_(C-F) = 1.8 Hz, 2 × Ar-C), 126.8 (Ar-C), 115.4 (d, ²J_(C-F) = 21.3 Hz, 2 × Ar-C), 99.3 (d, ¹J_(C-F) = 181.0 Hz, CHF), 77.5 (d, ²J_(C-F) = 20.4 Hz, C_qOHCHF overlapping with CDCl₃), 45.4 (CH₂Cl), 36.1 (d, ²J_(C-F) = 21.4 Hz, PhCH₂CHF), 34.8 (d, ³J_(C-F) = 2.8 Hz, CH₂COH), 26.5 (CH₂CH₂Cl); ¹⁹F NMR (470 MHz, CDCl₃) δ -115.3 (tt, ³J_(H-F) = 8.7 Hz, ⁴J_(H-F) = 5.4, 1F, Ar-F), -186.8 (ddd, ²J_(H-F) = 47.7 Hz, ³J_(H-F) = 41.4, 16.8 Hz, 1F, CHF); HRMS (ESI) m/z Calcd for C₁₈H₁₉Cl₂F₂ [M+Cl]⁻ 359.0787; Found: 359.0787.




3ai-major; 5-chloro-2-fluoro-3-(4-fluorophenyl)-1-phenylpentan-3-ol

Prepared according to general procedure GP to afford **3ai-major** as a yellow waxy solid (100 mg, 90%) after column chromatography ($R_f = 0.5$, hexane/Et₂O 9:1); IR (film)/cm⁻¹ 3564, 3065, 2964, 1899, 1513, 1228, 1010, 835; ¹H NMR (500 MHz, CDCl₃) δ 7.43–7.39 (m, 2H, 2 × Ar–H), 7.26–7.23 (m, 2H, 2 × Ar–H), 7.21–7.18 (m, 1H, Ar–H), 7.13–7.08 (m, 2H, 2 × Ar–H), 7.04 (d, $J = 7.3$ Hz, 2H, 2 × Ar–H), 4.76 (ddd, $^2J_{(H-F)} = 47.5$ Hz, $^3J_{(H-H)} = 9.9$, 2.1 Hz, 1H, CHFCH₂), 3.52 (dt, $^2J = 10.5$ Hz, $^3J = 5.9$ Hz, 1H, CHHCl), 3.19 (dt, $^2J = 10.5$ Hz, $^3J = 5.2$ Hz, 1H, CHHCl), 2.89 (ddd, $^3J_{(H-F)} = 17.4$ Hz, $^2J_{(H-H)} = 15.2$ Hz, $^3J_{(H-H)} = 9.9$ Hz, 1H, PhCHHCHF), 2.66–2.59 (m, 1H, CHHCH₂Cl), 2.49–2.37 (m, 3H, PhCHHCHF overlapping with O–H and CHHCH₂Cl); ¹³C NMR (125 MHz, CDCl₃) δ 163.2 (d, $^1J_{(C-F)} = 247.1$ Hz, Ar–C_q), 137.5 (d, $^3J_{(C-F)} = 0.5$ Hz, Ar–C_q), 135.6 (dd, $^3J_{(C-F)} = 4.8$ Hz, $^4J_{(C-F)} = 3.3$ Hz, Ar–C_q), 129.2 (2 × Ar–C), 128.6 (2 × Ar–C), 127.2 (d, $^3J_{(C-F)} = 8.0$ Hz, 2 × Ar–C), 126.7 (Ar–C), 115.9 (d, $^2J_{(C-F)} = 21.4$ Hz, 2 × Ar–C), 99.4 (d, $^1J_{(C-F)} = 181.2$ Hz, CHF), 77.6 (d, $^2J_{(C-F)} = 19.8$ Hz, C_qOHCHF), 42.4 (d, $^3J_{(C-F)} = 3.7$ Hz, CH₂CH₂Cl), 39.7 (CH₂Cl), 35.2 (d, $^2J_{(C-F)} = 21.7$ Hz, PhCH₂CHF); ¹⁹F NMR (470 MHz, CDCl₃) δ -114.5 (tt, $^3J_{(H-F)} = 8.6$ Hz, $^4J_{(H-F)} = 5.4$, 1F, Ar–F), -191.3 (ddd, $^2J_{(H-F)} = 47.4$ Hz, $^3J_{(H-F)} = 41.2$, 17.4 Hz, 1F, CHF); HRMS (ESI) m/z Calcd for C₁₇H₁₆ClF₂O [M–H]⁻ 309.0863; Found: 309.0861.




3ai-minor; 5-chloro-2-fluoro-3-(4-fluorophenyl)-1-phenylpentan-3-ol

Prepared according to general procedure GP to afford **3ai-minor** as a yellow waxy solid (67 mg, 90%) after column chromatography ($R_f = 0.4$, hexane/Et₂O 9:1); IR (film)/cm⁻¹ 3564, 3087, 2966, 1898, 1604, 1228, 1067, 837; ¹H NMR (500 MHz, CDCl₃) δ 7.51–7.49 (m, 2H, 2 × Ar–H), 7.30–7.27 (m, 2H, 2 × Ar–H), 7.25–7.21 (m, 1H, Ar–H), 7.15–7.09 (m, 4H, 4 × Ar–H), 4.69 (ddd, $^2J_{(H-F)} = 47.8$ Hz, $^3J_{(H-H)} = 10.0$, 2.1 Hz, 1H, CHFCH₂), 3.57 (ddd, $^2J = 11.0$ Hz, $^3J = 8.5$, 6.9 Hz, 1H, CHHCl), 3.42 (ddd, $^2J = 11.0$ Hz, $^3J = 8.7$, 5.4 Hz, 1H, CHHCl), 2.89 (ddd, $^3J_{(H-F)} = 41.9$ Hz, $^2J_{(H-H)} = 14.9$ Hz, $^3J_{(H-H)} = 2.1$ Hz, 1H, PhCHHCHF), 2.71 (s, 1H, O–H), 2.66–2.60 (m, 1H, CHHCH₂Cl), 2.58–2.51 (m, 1H, PhCHHCHF), 2.46–2.40 (m, 1H, CHHCH₂Cl); ¹³C NMR (125 MHz, CDCl₃) δ 162.5 (d, $^1J_{(C-F)} = 246.9$ Hz, Ar–C_q), 137.4 (d, $^3J_{(C-F)} = 0.7$ Hz, Ar–C_q), 135.9 (d, $^3J_{(C-F)} = 3.1$ Hz, Ar–C_q), 129.3 (2 × Ar–C), 128.7 (2 × Ar–C), 128.1 (2 × d, $^3J_{(C-F)} = 8.0$ Hz, 2 × Ar–C), 126.8 (Ar–C), 115.5 (d, $^2J_{(C-F)} = 21.3$ Hz, 2 × Ar–C), 98.9 (d, $^1J_{(C-F)} = 181.8$ Hz, CHF), 77.5 (d, $^2J_{(C-F)} = 21.3$ Hz, C_qOHCHF), 40.3 (d, $^3J_{(C-F)} = 3.2$ Hz, CH₂CH₂Cl), 40.2 (CH₂Cl), 35.9 (d, $^2J_{(C-F)} = 21.1$ Hz, PhCH₂CHF); ¹⁹F NMR (470 MHz, CDCl₃) δ -114.8 – -114.7 (m, 1F, Ar–F), -186.7 (ddd, $^2J_{(H-F)} = 47.8$ Hz, $^3J_{(H-F)} = 41.9$, 17.0 Hz, 1F, CHF); HRMS (ESI) m/z Calcd for C₁₇H₁₆ClF₂O [M–H]⁻ 309.0863; Found: 309.0898.




3aj; 2-(1-fluoro-2-phenylethyl)adamantan-2-ol

Prepared according to general procedure GP to afford **3aj** as a white waxy solid (98 mg, 60%) after column chromatography (R_f = 0.6, hexane/EtOAc 9:1); IR (film)/ cm^{-1} 3435, 3065, 2916, 2860, 1638, 1455, 1331, 699; ^1H NMR (500 MHz, CDCl_3) δ 7.34–7.31 (m, 2H, 2 \times Ar–H), 7.27–7.23 (m, 3H, 2 \times Ar–H overlapping with CDCl_3), 5.19 (ddd, $^2J_{(\text{H-F})} = 47.6$ Hz, $^3J_{(\text{H-H})} = 10.3$, 2.1 Hz, 1H, CHFCH_2), 3.07 (td, $^2J_{(\text{H-H})} = 15.0$ Hz, $^3J_{(\text{H-H})} = 10.3$ Hz, 1H, PhCHHCHF), 2.86 (ddd, $^3J_{(\text{H-F})} = 42.9$ Hz, $^2J_{(\text{H-H})} = 14.9$, 2.1 Hz, 1H, PhCHHCHF), 2.30 (d, $J = 12.4$ Hz, 1H, CH), 2.24 (d, $J = 12.4$ Hz, 1H, CH), 2.06 (s, 1H, CH), 1.94 (s, 2H, CH overlapping with O–H) 1.88–1.85 (m, 2H, 2 \times CH), 1.79–1.70 (m, 6H, 3 \times CH_2), 1.63–1.56 (m, 2H, CH_2); ^{13}C NMR (125 MHz, CDCl_3) δ 138.6 (d, $^3J_{(\text{C-F})} = 0.9$ Hz, Ar– C_q), 129.5 (2 \times Ar–C), 128.6 (2 \times Ar–C), 126.6 (Ar–C), 95.5 (d, $^1J_{(\text{C-F})} = 171.5$ Hz, CHF), 75.8 (d, $^2J_{(\text{C-F})} = 18.6$ Hz, COHCHF), 38.2 (CH_2), 34.6 (d, $^2J_{(\text{C-F})} = 21.7$ Hz, PhCH_2CHF), 34.2 (CH_2), 33.7 (CH_2), 33.6 (d, $^3J_{(\text{C-F})} = 4.8$ Hz, CHCOH), 32.9 (d, $^3J_{(\text{C-F})} = 1.5$ Hz, CHCOH), 32.7 (CH_2), 27.2 (CH), 27.1 (CH); ^{19}F NMR (470 MHz, CDCl_3) δ -201.2 – -201.0 (m, 1F, CHF); HRMS (ESI) m/z Calcd for $\text{C}_{18}\text{H}_{23}\text{FNaO}$ [$\text{M}+\text{Na}$] $^+$ 297.1625; Found: 297.1634.




3aj; 9-(1-fluoro-2-phenylethyl)-9H-fluoren-9-ol

Prepared according to general procedure GP to afford **3al** as a white waxy solid (116 mg, 64%) after column chromatography (R_f = 0.3, hexane/Et $_2$ O 8:2); IR (film)/ cm^{-1} 3524, 3392, 3063, 2924, 2852, 1607, 1451, 1064; ^1H NMR (500 MHz, CDCl_3) δ 7.72–7.67 (m, 2H, 2 \times Ar–H), 7.52 (d, $J = 7.5$ Hz, 1H, Ar–H), 7.46–7.41 (m, 2H, 2 \times Ar–H), 7.40–7.31 (m, 3H, 3 \times Ar–H), 7.22–7.19 (m, 2H, 2 \times Ar–H), 7.17–7.14 (m, 1H, 1 \times Ar–H), 6.99 (d, $J = 7.2$ Hz, 2H, 2 \times Ar–H), 5.20 (ddd, $^2J_{(\text{H-F})} = 48.9$ Hz, $^3J_{(\text{H-H})} = 9.8$, 2.2 Hz, 1H, CHFCH_2), 2.88 (s, 1H, O–H), 2.44 (ddd, $^3J_{(\text{H-F})} = 17.6$ Hz, $^2J_{(\text{H-H})} = 15.0$ Hz, $^3J_{(\text{H-H})} = 9.8$ Hz, 1H, PhCHHCHF), 2.31 (ddd, $^3J_{(\text{H-F})} = 40.1$ Hz, $^2J_{(\text{H-H})} = 15.0$, $^3J_{(\text{H-H})} = 2.2$ Hz, 1H, PhCHHCHF); ^{13}C NMR (125 MHz, CDCl_3) δ 144.9 (Ar– C_q), 144.8 (d, $^3J_{(\text{C-F})} = 5.5$ Hz, Ar– C_q), 140.6 (d, $^3J_{(\text{C-F})} = 2.8$ Hz, 2 \times Ar– C_q), 137.5 (Ar– C_q), 130.1 (Ar–C), 129.7 (Ar–C), 129.1 (2 \times Ar–C), 128.5 (2 \times Ar–C), 128.4 (2 \times Ar–C), 126.6 (Ar–C), 125.5 (d, $^4J_{(\text{C-F})} = 3.2$ Hz, Ar–C), 124.2 (Ar–C), 120.5 (Ar–C), 120.4 (Ar–C), 98.9 (d, $^1J_{(\text{C-F})} = 182.5$ Hz, CHF), 83.5 (d, $^2J_{(\text{C-F})} = 19.3$ Hz, C_qOHCHF), 36.3 (d, $^2J_{(\text{C-F})} = 21.1$ Hz, PhCH_2CHF); ^{19}F NMR (470 MHz, CDCl_3) δ -191.1 (ddd, $^2J_{(\text{H-F})} = 48.9$ Hz, $^3J_{(\text{H-F})} = 40.1$, 17.6 Hz, 1F, CHF); HRMS (ESI) m/z Calcd for $\text{C}_{21}\text{H}_{17}\text{FNaO}$ [$\text{M}+\text{Na}$] $^+$ 327.1161; Found: 327.1159.




3am-A; 3-fluoro-4-phenyl-2-(thiophen-2-yl)butan-2-ol

Prepared according to general procedure GP to afford **3am-A** as a yellow waxy solid (66 mg, 89%) after column chromatography (R_f = 0.45, hexane/Et $_2$ O 8:2); IR (film)/ cm^{-1} 3583, 3026, 2924, 1496, 1454, 1237, 697; ^1H NMR (500 MHz, CDCl_3) δ 7.28–7.26 (m, 3H, 3 \times Ar–H overlapping with CDCl_3), 7.23–7.20 (m, 1H, Ar–H), 7.17 (d, $J = 6.8$ Hz, 2H, 2 \times Ar–H), 7.04–7.01 (m, 2H, 2 \times Ar–H), 4.71 (ddd, $^2J_{(\text{H-F})} = 47.7$ Hz, $^3J_{(\text{H-H})} = 10.1$, 2.0 Hz, 1H, CHFCH_2), 2.99–2.91 (m, 1H, CHHCHF), 2.85–2.74 (m, 1H, CHHCHF), 2.42 (d, $^4J_{(\text{H-F})} = 1.5$ Hz, 1H, O–H), 1.75–1.74 (m, 3H, CH_3); ^{13}C NMR (125 MHz, CDCl_3) δ 147.9 (d, $^3J_{(\text{C-F})} = 4.2$ Hz, Ar– C_q), 137.8 (Ar– C_q), 129.1 (2 \times Ar–C), 128.4 (2 \times Ar–C), 127.1 (Ar–C), 126.5 (Ar–C), 124.7 (Ar–C), 123.4 (Ar–C), 99.3 (d, $^1J_{(\text{C-F})} = 182.2$ Hz, CHF), 75.2 (d, $^2J_{(\text{C-F})} = 21.7$ Hz, C_qOHCHF), 35.8 (d, $^2J_{(\text{C-F})} = 21.5$ Hz, PhCH_2CHF), 27.3 (d, $^3J_{(\text{C-F})} = 3.4$ Hz, CH_3); ^{19}F NMR (470 MHz, CDCl_3) -188.3 (ddd, $^2J_{(\text{H-F})} = 47.7$ Hz, $^3J_{(\text{H-F})} = 42.3$, 17.4 Hz, 1F, CHF); HRMS (ESI) m/z Calcd for $\text{C}_{14}\text{H}_{14}\text{FOS}$ [M-H] $^-$ 249.0755; Found: 249.0750.




3am-B; 3-fluoro-4-phenyl-2-(thiophen-2-yl)butan-2-ol

Prepared according to general procedure GP to afford **3am-B** as a yellow waxy solid (66 mg, 89%) after column chromatography ($R_f = 0.4$, hexane/Et₂O 8:2); IR (film)/cm⁻¹ 3419, 3030, 2917, 2849, 1604, 1455, 1265, 851; ¹H NMR (500 MHz, CDCl₃) δ 7.31–7.27 (m, 3H, 3 × Ar-H), 7.24–7.21 (m, 1H, Ar-H), 7.17 (d, $J = 7.3$ Hz, 2H, 2 × Ar-H), 7.07 (dd, $^3J = 3.5$ Hz, $^4J = 0.9$ Hz, 1H, Ar-H), 7.03 (dd, $^3J = 5.0$, 3.5 Hz, 1H, Ar-H), 4.74 (ddd, $^2J_{(H-F)} = 48.3$ Hz, $^3J_{(H-H)} = 10.0$, 2.0 Hz, 1H, CHFCH₂), 2.94–2.72 (m, 2H, 2 × CHHCHF), 2.58 (d, $^4J_{(H-F)} = 1.5$ Hz, 1H, O-H), 1.75 (d, $^4J_{(H-F)} = 1.6$ Hz, 3H, CH₃); ¹³C NMR (125 MHz, CDCl₃) δ 147.7 (d, $^3J_{(C-F)} = 2.4$ Hz, Ar-C_q), 137.7 (Ar-C_q), 129.3 (2 × Ar-C), 128.6 (2 × Ar-C), 127.1 (Ar-C), 126.7 (Ar-C), 125.3 (Ar-C), 124.4 (d, $^4J_{(C-F)} = 1.4$ Hz, Ar-C), 99.7 (d, $^1J_{(C-F)} = 181.4$ Hz, CHF), 75.1 (d, $^2J_{(C-F)} = 22.1$ Hz, C_qOHCHF), 36.5 (d, $^2J_{(C-F)} = 21.2$ Hz, PhCH₂CHF), 25.2 (d, $^3J_{(C-F)} = 3.0$ Hz, CH₃); ¹⁹F NMR (470 MHz, CDCl₃) -187.2 (ddd, $^2J_{(H-F)} = 48.3$ Hz, $^3J_{(H-F)} = 41.3$, 17.8 Hz, 1F, CHF); HRMS (ESI) m/z Calcd for C₁₄H₁₅FNaOS [M+Na]⁺ 273.0725; Found: 273.0723.




3an-A; 2-fluoro-1-phenylnonan-3-ol

Prepared according to general procedure GP to afford **3an-A** as (47 mg, 66%) after column chromatography ($R_f = 0.3$, hexane/EtOAc 95:5); IR (film)/cm⁻¹ 3400, 3064, 2928, 2857, 1605, 1455, 1060, 699; ¹H NMR (500 MHz, CDCl₃) δ 7.32–7.30 (m, 2H, 2 × Ar-H), 7.26–7.23 (m, 3H, 2 × Ar-H overlapping with CDCl₃), 4.55 (dddd, $^2J_{(H-F)} = 47.8$ Hz, $^3J_{(H-H)} = 7.9$, 5.3, 3.8 Hz, 1H, CHFCH₂), 3.61–3.52 (m, 1H, CHOH), 3.09–2.95 (m, 2H, 2 × PhCHHCHF), 1.77 (d, $^3J_{(H-H)} = 6.5$ Hz, 1H, O-H), 1.58–1.46 (m, 4H, 2 × CH₂), 1.37–1.26 (m, 6H, 3 × CH₂), 0.88 (t, $^3J_{(H-H)} = 6.9$ Hz, 3H, CH₃); ¹³C NMR (125 MHz, CDCl₃) δ 137.1 (d, $^3J_{(C-F)} = 5.2$ Hz, Ar-C_q), 129.5 (2 × Ar-C), 128.7 (2 × Ar-C), 126.8 (Ar-C), 96.4 (d, $^1J_{(C-F)} = 173.9$ Hz, CHF), 72.2 (d, $^2J_{(C-F)} = 19.5$ Hz, COHCHF), 37.8 (d, $^2J_{(C-F)} = 21.9$ Hz, PhCH₂CHF), 33.3 (d, $^3J_{(C-F)} = 4.0$ Hz, CH₂CHOH), 31.9 (CH₂), 29.4 (CH₂), 25.6 (CH₂), 22.7 (CH₂), 14.2 (CH₃); ¹⁹F NMR (470 MHz, CDCl₃) δ -195.0 – -194.7 (m, 1F, CHF); HRMS (ESI) m/z Calcd for C₁₅H₂₃FNaO [M+Na]⁺ 261.1631; Found: 261.1623.




3an-B; 2-fluoro-1-phenylnonan-3-ol

Prepared according to general procedure GP to afford **3an-B** as (47 mg, 66%) after column chromatography ($R_f = 0.2$, hexane/Et₂O 95:5); IR (film)/cm⁻¹ 3584, 3402, 3065, 2926, 2857, 1497, 1455, 1061, 699; ¹H NMR (500 MHz, CDCl₃) δ 7.33–7.30 (m, 2H, 2 × Ar-H), 7.26–7.23 (m, 3H, 2 × Ar-H overlapping with CDCl₃), 4.66–4.53 (m, 1H, CHFCH₂), 3.80–3.76 (m, 1H, CHOH), 3.07–2.88 (m, 2H, 2 × PhCHHCHF), 1.78 (d, $^3J_{(H-H)} = 5.1$ Hz, 1H, O-H), 1.62–1.47 (m, 4H, 2 × CH₂), 1.34–1.30 (m, 6H, 3 × CH₂), 0.88 (t, $^3J_{(H-H)} = 6.9$ Hz, 3H, CH₃); ¹³C NMR (125 MHz, CDCl₃) δ 137.5 (d, $^3J_{(C-F)} = 2.2$ Hz, Ar-C_q), 129.4 (2 × Ar-C), 128.6 (2 × Ar-C), 126.7 (Ar-C), 96.8 (d, $^1J_{(C-F)} = 173.1$ Hz, CHF), 72.8 (d, $^2J_{(C-F)} = 22.1$ Hz, COHCHF), 36.4 (d, $^2J_{(C-F)} = 21.3$ Hz, PhCH₂CHF), 32.1 (d, $^3J_{(C-F)} = 5.2$ Hz, CH₂CHOH), 31.9 (CH₂), 29.4 (CH₂), 25.7 (CH₂), 22.7 (CH₂), 14.2 (CH₃); ¹⁹F NMR (470 MHz, CDCl₃) δ -188.5 – -188.2 (m, 1F, CHF); HRMS (ESI) m/z Calcd for C₁₅H₂₃FNaO [M+Na]⁺ 261.1631; Found: 261.1613.




3ap; 1-(4-chlorophenyl)-2-fluoro-3-phenylpropan-1-ol

Prepared according to general procedure GP to afford **3ap** (dr = 50:50, 119 mg, 75%) obtained as a white waxy solid after column chromatography (R_f = 0.3, hexane/Et₂O 9:1); *Inseparable mixture of diastereoisomers* dr = 77:23; IR (film)/cm⁻¹ 3396, 3031, 2922, 2850, 1600, 1493, 1455, 1090, 699; ¹H NMR (500 MHz, CDCl₃, *mixture of diastereoisomers*) δ 7.37–7.22 (m overlapping CDCl₃, 7H major + 2.1H minor, Ar–H), 7.18–7.16 (m, 2H major + 0.6H minor, Ar–H), 4.89–4.64 (m, 2H major + 0.6H minor, CHFCH₂ overlapping with CHOH), 2.99 (ddd, ³J_(H-F) = 19.2 Hz, ²J_(H-H) = 14.7 Hz ³J_(H-H) = 8.7 Hz, 0.3H minor, PhCHHCHF), 2.90–2.77 (m, 2H major + 0.3H minor, PhCHHCHF), 2.53 (s, 1H major, O–H), 2.29 (s, 0.3H minor, O–H); ¹³C NMR (125 MHz, CDCl₃, *mixture of diastereoisomers*) δ 137.9 (d, ³J_(C-F) = 4.9 Hz, 2 × Ar–C_q), 136.6 (d, ³J_(C-F) = 3.3 Hz, 2 × Ar–C_q), 134.5 (Ar–C_q), 134.2 (Ar–C_q), 129.5 (2 × Ar–C), 129.4 (2 × Ar–C), 129.0 (2 × Ar–C), 128.9 (2 × Ar–C), 128.7 (2 × Ar–C), 128.6 (4 × Ar–C), 128.2 (2 × Ar–C), 127.0 (Ar–C), 126.8 (Ar–C), 97.0 (d, ¹J_(C-F) = 177.8 Hz, CHF), 96.5 (d, ¹J_(C-F) = 177.0 Hz, CHF), 74.8 (d, ²J_(C-F) = 20.8 Hz, COHCHF), 74.3 (d, ²J_(C-F) = 23.5 Hz, COHCHF), 37.4 (d, ²J_(C-F) = 21.1 Hz, PhCH₂CHF), 36.1 (d, ²J_(C-F) = 21.1 Hz, PhCH₂CHF); ¹⁹F NMR (470 MHz, CDCl₃) δ -188.0 – -187.8 (m, 0.3F minor, CHF), -189.7 – -189.5 (m, 1F major, CHF); HRMS (ESI) m/z Calcd for C₁₅H₁₂ClO [(M-HF)-H]⁻ 243.0582; Found: 243.0369.




3aq; tert-butyl (2-fluoro-1,3-diphenylpropyl)carbamate

Prepared according to general procedure GP to afford **3aq** (dr = 60:40) obtained as a yellow oil (dr = 75:25 128 mg, 65%) after column chromatography (R_f = 0.2, hexane/EtOAc/Net₃ 9:1:0.1); *Inseparable mixture of diastereoisomers*; IR (film)/cm⁻¹ 3433, 3031, 2918, 2850, 1704, 1495, 1366, 1166, 876; ¹H NMR (500 MHz, CDCl₃, *mixture of diastereoisomers*) δ 7.40–7.22 (m overlapping with CDCl₃, 8H major + 3H minor, Ar–H), 7.14 (d, J = 7.3 Hz, 2H, 2 × Ar–H), 5.34 (broad s, 1H major + 0.3H minor, 2 × N–H), 5.09–4.59 (m, 2H major + 0.6H minor, 2 × CHFCH₂ overlapping with 2 × CHNH), 3.13–2.94 (m, 0.6H minor, 2 × PhCHHCHF), 2.76–2.67 (m, 2H major, 2 × PhCHHCHF), 1.46 (s, 1.8H minor, 3 × CH₃), 1.41 (s, 9H major, 3 × CH₃); ¹³C NMR (125 MHz, CDCl₃, *mixture of diastereoisomers*) δ 155.6 (CO₂N), 155.1 (CO₂N), 136.7 (d, ³J_(C-F) = 2.4 Hz, 2 × Ar–C_q), 136.7 (d, ³J_(C-F) = 3.6 Hz, 2 × Ar–C_q), 129.5 (2 × Ar–C), 129.3 (2 × Ar–C), 128.8 (2 × Ar–C), 128.7 (2 × Ar–C), 128.5 (2 × Ar–C), 128.6 (4 × Ar–C), 128.2 (Ar–C), 127.8 (Ar–C), 127.0 (2 × Ar–C), 126.9 (2 × Ar–C), 96.7 (d, ¹J_(C-F) = 173.2 Hz, CHF), 96.0 (d, ¹J_(C-F) = 181.5 Hz, CHF), 80.1 (2 × OC(CH₃)₃), 57.7 (d, ²J_(C-F) = 19.1 Hz, 2 × CNHCHF), 38.9 (d, ²J_(C-F) = 22.1 Hz, PhCH₂CHF), 38.7 (d, ²J_(C-F) = 20.5 Hz, PhCH₂CHF), 29.8 (3 × CH₃), 28.5 (3 × CH₃); ¹⁹F NMR (470 MHz, CDCl₃) δ -192.2 – -192.0 (m, 0.3F minor, CHF), -193.6 – -193.3 (m, 1F major, CHF); HRMS (ESI) m/z Calcd for C₂₀H₂₄FNNaO₂ [M+Na]⁺ 352.1683; Found: 352.1689.




3ar; (1-fluoro-2-phenylethyl)dimethyl(phenyl)silane

Prepared according to general procedure GP, with slight modifications. The solution resulting from the microfluidic system was quenched with 150 μL of MeOH, filtered on Na_2SO_4 and concentrated under reduced pressure to afford **3ar** as a colorless oil (47 mg, 30%) after column chromatography ($R_f = 0.1$, hexane/Et₂O 9:1); IR (film)/ cm^{-1} 3068, 3028, 2958, 2925, 1953, 1604, 1251, 834; ¹H NMR (500 MHz, CDCl₃) δ 7.56 (dd, $J = 7.5, 1.6$ Hz, 2H, 2 \times Ar-H), 7.42–7.39 (m, 3H, 3 \times Ar-H), 7.28–7.25 (m, 2H, 2 \times Ar-H overlapping with CDCl₃), 7.21–7.17 (m, 3H, 3 \times Ar-H), 4.85 (ddd, $^2J_{\text{(H-F)}} = 46.1$ Hz, $^3J_{\text{(H-H)}} = 10.8, 3.6$ Hz, 1H, CHFCH₂), 3.03 (ddd, $^3J_{\text{(H-F)}} = 17.9$ Hz, $^2J_{\text{(H-H)}} = 15.0$ Hz, $^3J_{\text{(H-H)}} = 10.8$ Hz, 1H, PhCHHCHF), 2.85 (ddd, $^3J_{\text{(H-F)}} = 41.8$ Hz, $^2J_{\text{(H-H)}} = 15.0$ Hz, $^3J_{\text{(H-H)}} = 3.6$ Hz, 1H, PhCHHCHF), 0.38 (s, 3H, SiCH₃), 0.36 (s, 3H, SiCH₃); ¹³C NMR (125 MHz, CDCl₃) δ 139.2 (d, $^3J_{\text{(C-F)}} = 3.8$ Hz, Ar-C_q), 135.5 (d, $^3J_{\text{(C-F)}} = 3.0$ Hz, Ar-C_q), 134.3 (2 \times Ar-C), 129.8 (Ar-C), 129.1 (2 \times Ar-C), 128.5 (2 \times Ar-C), 128.1 (2 \times Ar-C), 126.5 (Ar-C), 92.7 (d, $^1J_{\text{(C-F)}} = 167.2$ Hz, CHF), 38.4 (d, $^2J_{\text{(C-F)}} = 19.7$ Hz, PhCH₂CHF), -5.3 (CH₃), -5.5 (CH₃); ¹⁹F NMR (470 MHz, CDCl₃) δ -186.7 (ddd, $^2J_{\text{(H-F)}} = 46.1$ Hz, $^3J_{\text{(H-F)}} = 41.8, 17.9$ Hz, 1F, CHF); The product **3ar** decomposed during high-resolution mass (HRMS) analysis.




3as; tributyl(1-fluoro-2-phenylethyl)stannane

Prepared according to general procedure GP to afford **3as** as a colorless oil (156 mg, 63%) after column chromatography ($R_f = 0.3$, hexane); IR (film)/ cm^{-1} 3584, 3064, 2956, 2924, 2852, 1495, 1455, 1075, 960; ¹H NMR (500 MHz, CDCl₃) δ 7.31–7.28 (m, 2H, 2 \times Ar-H), 7.24–7.21 (m, 3H, 3 \times Ar-H), 4.91 (ddd, $^2J_{\text{(H-F)}} = 46.1$ Hz, $^3J_{\text{(H-H)}} = 8.9, 5.8$ Hz, 1H, CHFCH₂), 3.36–3.27 (m, 1H, PhCHHCHF), 3.13 (ddd, $^3J_{\text{(H-F)}} = 32.8$ Hz, $^2J_{\text{(H-H)}} = 14.3$ Hz, $^3J_{\text{(H-H)}} = 5.8$ Hz, 1H, PhCHHCHF), 1.48–1.41 (m, 6H, 3 \times CH₂), 1.32–1.24 (m, 6H, 3 \times CH₂), 0.90–0.83 (m, 15H, 3 \times CH₃ overlapping with 3 \times CH₂); ¹³C NMR (125 MHz, CDCl₃) δ 139.3 (d, $^3J_{\text{(C-F)}} = 6.7$ Hz, Ar-C_q), 129.2 (2 \times Ar-C), 128.6 (2 \times Ar-C), 126.6 (Ar-C), 95.7 (d, $^1J_{\text{(C-F)}} = 189.4$ Hz, CHF), 42.4 (d, $^2J_{\text{(C-F)}} = 18.5$ Hz, PhCH₂CHF), 29.1 (3 \times CH₂), 27.5 (3 \times CH₂), 29.1 (3 \times CH₂), 13.8 (3 \times CH₃), 9.1 (d, $^3J_{\text{(C-F)}} = 3.1$ Hz, 3 \times CH₂); ¹⁹F NMR (470 MHz, CDCl₃) δ -208.9 (ddd, $^2J_{\text{(H-F)}} = 46.1$ Hz, $^3J_{\text{(H-F)}} = 32.8, 21.6$ Hz, 1F, CHF); HRMS (ESI) m/z Calcd for C₂₀H₃₄FSn [M-H]⁻ 413.1672; Found: 413.1667.



3at; 2-fluoro-1,3-diphenylpropan-1-one


Prepared according to general procedure GP to afford **3at** as a white solid (97 mg, 71%) after column chromatography ($R_f = 0.4$, hexane/Et₂O 9:1); ¹H NMR (500 MHz, CDCl₃) δ 7.95–7.93 (m, 2H, 2 \times Ar-H), 7.62–7.59 (m, 1H, Ar-H), 7.50–7.46 (m, 2H, 2 \times Ar-H), 7.34–7.25 (m, 5H, 5 \times Ar-H), 5.74 (ddd, $^2J_{\text{(H-F)}} = 49.0$ Hz, $^3J_{\text{(H-H)}} = 8.3, 4.0$ Hz, 1H, CHFCH₂), 3.38–3.20 (m, 2H, 2 \times PhCHHCHF); in according to spectral data reported in the literature.⁹



3au; 2-fluoro-5-methyl-1-phenylhexan-3-one


Prepared according to general procedure GP to afford **3au** as a white waxy solid (61 mg, 49%) after column chromatography ($R_f = 0.3$, hexane/EtOAc 8:2); IR (film)/ cm^{-1} 3032, 2958, 2929, 2872, 1722, 1497, 1455, 1368,

1047; ^1H NMR (500 MHz, CDCl_3) δ 7.31 (t, $J = 7.2$ Hz, 2H, $2 \times \text{Ar-H}$), 7.27–7.26 (m, 1H, Ar-H overlapping with CDCl_3), 7.23 (d, $J = 7.2$ Hz, 2H, $2 \times \text{Ar-H}$), 4.91 (ddd, $^2J_{(\text{H-F})} = 49.8$ Hz, $^3J_{(\text{H-H})} = 7.7$, 3.7 Hz, 1H, CHFCH_2), 3.18 (ddd, $^3J_{(\text{H-F})} = 29.3$ Hz, $^2J_{(\text{H-H})} = 14.8$ Hz, $^3J_{(\text{H-H})} = 3.7$ Hz, 1H, PhCHHCHF), 3.03 (ddd, $^3J_{(\text{H-F})} = 25.9$ Hz, $^2J_{(\text{H-H})} = 14.8$ Hz, $^3J_{(\text{H-H})} = 7.7$ Hz, 1H, PhCHHCHF), 2.46 (ddd, $^2J_{(\text{H-H})} = 17.5$ Hz, $^4J_{(\text{H-F})} = 6.5$ Hz, $^3J_{(\text{H-H})} = 3.7$ Hz, 1H, CHHCO), 2.24 (ddd, $^2J_{(\text{H-H})} = 17.5$ Hz, $^4J_{(\text{H-F})} = 7.0$ Hz, $^3J_{(\text{H-H})} = 2.9$ Hz, 1H, CHHCO), 2.16–2.08 (m, 1H, $\text{CH}_2\text{CH}(\text{CH}_3)_2$), 0.90 (d, $^3J = 6.7$ Hz, 3H, CH_3), 0.85 (d, $^3J = 6.6$ Hz, 3H, CH_3); ^{13}C NMR (125 MHz, CDCl_3) δ 209.5 (d, $^2J_{(\text{C-F})} = 24.4$ Hz, CO), 135.6 (Ar- C_q), 129.7 ($2 \times \text{Ar-C}$), 128.7 ($2 \times \text{Ar-C}$), 127.2 (Ar-C), 96.1 (d, $^1J_{(\text{C-F})} = 187.6$ Hz, CHF), 47.5 (s, CH_2CO), 38.3 (d, $^2J_{(\text{C-F})} = 20.5$ Hz, PhCH_2CHF), 23.5 (d, $^4J_{(\text{C-F})} = 1.9$ Hz, $\text{CH}_2\text{CH}(\text{CH}_3)_2$), 22.7 (CH_3), 22.6 (CH_3); ^{19}F NMR (470 MHz, CDCl_3) δ -190.3 – -190.1 (m, 1F, CHF); HRMS (ESI) m/z Calcd for $\text{C}_{13}\text{H}_{17}\text{FNaO}$ [$\text{M}+\text{Na}$] $^+$ 231.1156; Found: 231.1161.



3ba; 2-fluoro-1,1,4-triphenylbutan-1-ol


Prepared according to general procedure GP to afford **3ba** as a white waxy solid (182 mg, 95%) after column chromatography ($R_f = 0.3$, hexane/ Et_2O 9:1); IR (film)/ cm^{-1} 3400, 2917, 1599, 1493, 1447, 1168, 976, 748; ^1H NMR (500 MHz, CDCl_3) δ 7.50 (d, $J = 8.1$ Hz, 2H, $2 \times \text{Ar-H}$), 7.32 (t, $J = 8.0$ Hz, 4H, $4 \times \text{Ar-H}$), 7.28–7.23 (m, 5H, $5 \times \text{Ar-H}$, overlapping with CDCl_3), 7.22–7.17 (m, 2H, $2 \times \text{Ar-H}$), 7.10 (d, $J = 7.2$ Hz, 2H, $2 \times \text{Ar-H}$), 5.36 (ddd, $^2J_{(\text{H-F})} = 47.2$ Hz, $^3J_{(\text{H-H})} = 10.1$, 2.0 Hz, 1H, CHFCH_2), 2.88–2.82 (m, 1H, PhCHHCH_2), 2.65–2.59 (m, 2H, PhCHHCH_2 overlapping with O-H), 2.17–2.05 (m, 1H, CHHCHF), 1.73–1.57 (m, 1H, CHHCHF); ^{13}C NMR (125 MHz, CDCl_3) δ 144.8 (Ar- C_q), 143.1 (d, $^3J_{(\text{C-F})} = 4.2$ Hz, Ar- C_q), 141.3 (Ar- C_q), 128.6 ($2 \times \text{Ar-C}$), 128.5 ($4 \times \text{Ar-C}$), 128.4 ($2 \times \text{Ar-C}$), 127.5 (Ar-C), 127.4 (Ar-C), 126.9 (d, $^4J_{(\text{C-F})} = 1.7$ Hz, $2 \times \text{Ar-C}$), 126.1 (Ar-C), 126.0 ($2 \times \text{Ar-C}$), 95.3 (d, $^1J_{(\text{C-F})} = 178.6$ Hz, CHF), 79.2 (d, $^2J_{(\text{C-F})} = 20.7$ Hz, C_qOHCHF), 31.8 (d, $^3J_{(\text{C-F})} = 3.5$ Hz, PhCH_2CH_2), 30.6 (d, $^2J_{(\text{C-F})} = 21.3$ Hz, $\text{CH}_2\text{CH}_2\text{CHF}$); ^{19}F NMR (470 MHz, CDCl_3) δ -190.3 (ddd, $^2J_{(\text{H-F})} = 47.4$ Hz, $^3J_{(\text{H-F})} = 40.1$, 13.4 Hz, 1F, CHF); HRMS (ESI) m/z Calcd for $\text{C}_{22}\text{H}_{21}\text{FNaO}$ [M-H] 343.1469; Found: 343.1449.



3bm; 3-fluoro-5-phenyl-2-(thiophen-2-yl)pentan-2-ol


Prepared according to general procedure GP to afford **3bm** (dr = 60:40) obtained as a waxy solid (dr = 70:30, 123 mg, 78%) after column chromatography ($R_f = 0.3$, hexane/ Et_2O 85:15); *Inseparable mixture of diastereoisomers*; IR (film)/ cm^{-1} 3435, 3027, 2918, 2849, 1496, 1455, 1237, 698; ^1H NMR (500 MHz, CDCl_3 , *mixture of diastereoisomers*) δ 7.37–7.12 (m overlapping with CDCl_3 , 6H *major* + 2.4H *minor*, Ar-H), 6.98–6.88 (m, 2H *major* + 0.8H *minor*, Ar-H), 4.61–4.43 (m, 1H *major* + 0.4H *minor*, CHFCH_2), 2.89–2.81 (m, 1H *major* + 0.4H *minor*, PhCHHCH_2), 2.66–2.58 (m, 1H *major* + 0.4H *minor*, PhCHHCH_2), 2.54 (d, $^4J_{(\text{H-F})} = 1.9$ Hz, 1H *major*, O-H), 2.36 (d, $^4J_{(\text{H-F})} = 1.2$ Hz, 0.4H *minor*, O-H), 2.01–1.97 (m, 1H *major* + 0.4H *minor*), 1.67 (d, $^4J_{(\text{H-F})} = 2.0$ Hz, 1.2H *minor*, CH_3), 1.66 (d, $^4J_{(\text{H-F})} = 1.4$ Hz, 3H *major*, CH_3); ^{13}C NMR (125 MHz, CDCl_3 , *mixture of diastereoisomers*) δ 148.0 (d, $^3J_{(\text{C-F})} = 3.8$ Hz, Ar- C_q), 147.9 (d, $^3J_{(\text{C-F})} = 2.9$ Hz, Ar- C_q), 141.3 (Ar- C_q), 141.2 (Ar- C_q), 128.6 ($8 \times \text{Ar-C}$), 127.1 (Ar-C), 127.0 (Ar-C), 126.2 (Ar-C), 126.1 (Ar-C), 125.2 (Ar-C), 124.7 (Ar-C), 124.2 (d, $^4J_{(\text{C-F})} = 1.2$ Hz, Ar-C), 123.5 (d, $^4J_{(\text{C-F})} = 0.7$ Hz, Ar-C), 98.4 (d, $^1J_{(\text{C-F})} = 178.5$ Hz, CHF), 98.1 (d, $^1J_{(\text{C-F})} = 179.2$ Hz, CHF), 75.2 (d, $^2J_{(\text{C-F})} = 21.4$ Hz, C_qOHCHF), 75.1 (d, $^2J_{(\text{C-F})} = 21.8$ Hz, C_qOHCHF), 31.9 (d, $^3J_{(\text{C-F})} = 2.8$ Hz, PhCH_2CH_2), 31.8 (d, $^3J_{(\text{C-F})} = 3.2$ Hz, PhCH_2CH_2), 31.9 (d, $^2J_{(\text{C-F})} = 21.1$ Hz, $\text{CH}_2\text{CH}_2\text{CHF}$), 31.1 (d, $^2J_{(\text{C-F})} = 21.3$ Hz, $\text{CH}_2\text{CH}_2\text{CHF}$), 27.3 (d, $^3J_{(\text{C-F})} = 3.6$ Hz, CH_3), 24.9 (d, $^3J_{(\text{C-F})} = 3.0$ Hz, CH_3); ^{19}F NMR (470 MHz,

CDCl₃) δ -190.0 (ddd, $^2J_{(H-F)} = 48.5$ Hz, $^3J_{(H-F)} = 39.0$, 16.0 Hz, 1F *major*, CHF), -191.0 (ddd, $^2J_{(H-F)} = 47.9$ Hz, $^3J_{(H-F)} = 40.9$, 13.8 Hz, 0.4F *minor*, CHF); HRMS (ESI) *m/z* Calcd for C₁₅H₁₆FOS [M-H]⁻ 263.0911; Found: 263.0917; Calcd for C₁₅H₁₅OS [(M-HF)-H]⁻ 243.0849; Found: 243.0842 .



3bn; 3-fluoro-1-phenyldecan-4-ol


Prepared according to general procedure GP to afford **3bn** as a white waxy solid (dr = 60:40, 75 mg, 50%) after column chromatography (*R_f* = 0.5, hexane/EtOAc 9:1); *Inseparable mixture of diastereoisomers*; IR (film)/cm⁻¹ 3400, 3028, 2925, 2856, 1496, 1455, 1029, 699; ¹H NMR (500 MHz, CDCl₃, *mixture of diastereoisomers*) δ 7.30 (t, *J* = 7.4 Hz, 2H *major* + 1.2H *minor*, Ar-H), 7.22–7.19 (m, 3H *major* + 1.8H *minor*, Ar-H), 4.39 (dddd, $^2J_{(H-F)} = 48.0$ Hz, $^3J_{(H-H)} = 10.1$, 3.8, 2.6 Hz, 1H *major*, CH₂CHFCHOH, overlapping with *minor*'s CH₂CHFCHOH), 4.33 (dddd, $^2J_{(H-F)} = 48.6$ Hz, $^3J_{(H-H)} = 9.3$, 4.6, 3.4 Hz, 0.6H *minor*, CH₂CHFCHOH, overlapping with *major*'s CH₂CHFCHOH), 3.77–3.73 (m, 1H *major*, CHOH), 3.60–3.56 (m, 0.6H *minor*, CHOH), 2.93–2.82 (m, 1H *major* + 0.6H *minor*, PhCHHCH₂), 2.75–2.66 (m, 1H *major* + 0.6H *minor*, PhCHHCH₂), 2.11–2.02 (m, 1H *major* + 0.6H *minor*, CH₂CHHCHF), 1.92–1.79 (m, 1H *major* + 0.6H *minor*, CH₂CHHCHF), 1.72 (broad s, 1H *major*, O-H), 1.56 (broad s, 0.6H *minor*, O-H), 1.48–1.26 (m, 10H *major* + 6H *minor*, CH₂), 0.88 (t, *J* = 6.9 Hz, 3H *major* + 1.8H *minor*, CH₃); ¹³C NMR (125 MHz, CDCl₃, *mixture of diastereoisomers*) δ 141.5 (Ar-C_q), 141.4 (Ar-C_q), 128.6 (8 × Ar-C), 126.2 (2 × Ar-C), 95.8 (d, $^1J_{(C-F)} = 170.2$ Hz, CHF), 95.7 (d, $^1J_{(C-F)} = 170.1$ Hz, CHF), 73.2 (d, $^2J_{(C-F)} = 19.5$ Hz, COHCHF), 73.1 (d, $^2J_{(C-F)} = 21.6$ Hz, COHCHF), 33.1 (d, $^2J_{(C-F)} = 21.2$ Hz, CH₂CH₂CHF), 33.0 (d, $^3J_{(C-F)} = 9.5$ Hz, CH₂CHOH), 31.9 (d $^3J_{(C-F)} = 6.3$ Hz, CH₂CHOH, overlapping with CH₂), 31.5 (d, $^3J_{(C-F)} = 3.4$ Hz, PhCH₂CH₂), 31.4 (d, $^3J_{(C-F)} = 4.4$ Hz, PhCH₂CH₂), 31.3 (d, $^2J_{(C-F)} = 21.1$ Hz, CH₂CH₂CHF), 29.9 (CH₂), 29.4 (2 × CH₂), 25.8 (CH₂), 25.5 (CH₂), 22.7 (2 × CH₂), 14.2 (2 × CH₃); ¹⁹F NMR (470 MHz, CDCl₃) δ -192.1 (ddt, $^2J_{(H-F)} = 48.0$ Hz, $^3J_{(H-F)} = 39.3$, 14.8 Hz, 1F *major*, CHF), -196.7 – -196.5 (m, 0.6F *minor*, CHF); HRMS (ESI) *m/z* Calcd for C₁₆H₂₄FO [M-H]⁻ 251.1817; Found: 251.1815.



3bo; 1-(benzo[d][1,3]dioxol-5-yl)-2-fluoro-4-phenylbutan-1-ol


Prepared according to general procedure GP to afford **3bo** as a white waxy solid (dr = 50:50, 103 mg, 60%) after column chromatography (*R_f* = 0.2, hexane/Et₂O 8:2); *Inseparable mixture of diastereoisomers*; IR (film)/cm⁻¹ 3408, 3027, 2917, 1504, 1488, 1247, 1038, 930; ¹H NMR (500 MHz, CDCl₃, *mixture of diastereoisomers*) δ 7.28–7.24 (m, 4H, 4 × Ar-H), 7.19–7.10 (m, 6H, 6 × Ar-H), 6.88–6.82 (m, 2H, 2 × Ar-H), 6.78–6.77 (m, 4H, 4 × Ar-H), 5.96 (s, 2H, CH₂O₂), 5.95 (s, 2H, CH₂O₂), 4.79–4.43 (m, 4H, 2 × CH₂CHFCHOH overlapping with 2 × CHFCHOH), 2.87–2.80 (m, 2H, 2 × PhCHHCH₂), 2.66–2.59 (m, 2H, 2 × PhCHHCH₂), 2.54 (t, *J* = 2.7 Hz, 1H, O-H), 2.17 (d, $^4J_{(H-F)} = 3.6$ Hz, 1H, O-H), 2.04–1.60 (m, 4H, 4 × CH₂CHHCHF); ¹³C NMR (125 MHz, CDCl₃, *mixture of diastereoisomers*) δ 148.1 (Ar-C_q), 148.0 (Ar-C_q), 147.9 (Ar-C_q), 147.5 (Ar-C_q), 133.2 (d, $^3J_{(C-F)} = 4.9$ Hz, Ar-C_q), 132.9 (d, $^3J_{(C-F)} = 6.5$ Hz, Ar-C_q), 128.6 (3 × Ar-C), 128.5 (Ar-C), 126.2 (2 × Ar-C), 120.9 (Ar-C), 120.3 (Ar-C), 119.5 (Ar-C), 108.5 (Ar-C), 108.3 (Ar-C), 108.2 (Ar-C), 107.5 (Ar-C), 107.3 (2 × Ar-C), 106.5 (Ar-C), 101.3 (2 × CH₂O₂) 96.6 (d, $^1J_{(C-F)} = 174.1$ Hz, CHF), 95.6 (d, $^1J_{(C-F)} = 174.3$ Hz, CHF), 76.4 (d, $^2J_{(C-F)} = 20.9$ Hz, COHCHF), 75.2 (d, $^2J_{(C-F)} = 22.6$ Hz, COHCHF), 32.9 (d, $^2J_{(C-F)} = 20.6$ Hz, CH₂CH₂CHF), 31.5 (d, $^3J_{(C-F)} = 9.5$ Hz, PhCH₂CH₂), 31.4 (d $^2J_{(C-F)} = 20.4$ Hz, CH₂CH₂CHF), 31.3 (d, $^3J_{(C-F)} = 3.7$ Hz, PhCH₂CH₂), 31.4 (d, $^3J_{(C-F)} = 4.4$ Hz, PhCH₂CH₂), 31.3 (d, $^2J_{(C-F)} = 21.1$ Hz, CH₂CH₂CHF), 29.9 (CH₂), 29.4 (2 × CH₂), 25.8 (CH₂), 25.5 (CH₂),

22.7 (2 × CH₂), 14.2 (2 × CH₃); ¹⁹F NMR (470 MHz, CDCl₃) δ -191.2 (ddt, ²J_(H-F) = 47.9 Hz, ³J_(H-F) = 37.8, 14.4 Hz, 1F, CHF), -190.0 – -189.8 (m, 1F, CHF); HRMS (ESI) m/z Calcd for C₁₇H₁₇FNao₃ [M+Na]⁺ 311.1054; Found: 311.1057.




3bt; 2-fluoro-1,4-diphenylbutan-1-one

Prepared according to general procedure GP to afford **3bt** as a white waxy solid (87 mg, 60%) after column chromatography (*R_f* = 0.4, hexane/Et₂O 98:2); IR (film)/cm⁻¹ 3029, 2959, 2930, 2863, 1640, 1580, 1496, 1449, 1249; ¹H NMR (500 MHz, CDCl₃) δ 7.87 (d, *J* = 7.6 Hz, 2H, 2 × Ar-H), 7.60–7.57 (m, 1H, Ar-H), 7.45 (t, *J* = 7.8 Hz, 2H, 2 × Ar-H), 7.32 (t, *J* = 7.5 Hz, 2H, 2 × Ar-H), 7.25–7.22 (m, 3H, 3 × Ar-H), 5.61–5.49 (m, 1H, CHF), 2.94–2.82 (m, 2H, PhCH₂CH₂), 2.32–2.22 (m, 2H, CH₂CHF); ¹³C NMR (125 MHz, CDCl₃) δ 196.7 (d, ²J_(C-F) = 19.2 Hz, CO), 140.4 (Ar-C_q), 133.9 (Ar-C), 129.0 (d, ³J_(C-F) = 3.6 Hz, Ar-C_q), 128.9 (2 × Ar-C), 128.8 (6 × Ar-C), 126.5 (Ar-C), 92.7 (d, ¹J_(C-F) = 183.4 Hz, CHF), 34.5 (d, ²J_(C-F) = 21.4 Hz, CH₂CH₂CHF), 31.0 (d, ³J_(C-F) = 3.2 Hz, PhCH₂CH₂); ¹⁹F NMR (470 MHz, CDCl₃) δ -191.5 – -191.3 (m, 1F, CHF); HRMS (ESI) m/z Calcd for C₁₆H₁₅FNao [M+Na]⁺ 265.0999; Found: 265.0995.



3bv-A; benzyl (1-fluoro-3-phenylpropyl)(phenyl)-I⁴-sulfanylidene carbamate


Prepared according to general procedure GP to afford **3bv-A** as yellow oil (35 mg, 30%) after column chromatography (*R_f* = 0.3, hexane/Et₂O 6:4); IR (film)/cm⁻¹ 3063, 3030, 2918, 2850, 1738, 1644, 1454, 1254; ¹H NMR (500 MHz, CDCl₃) δ 7.81 (d, *J* = 8.0 Hz, 2H, 2 × Ar-H), 7.63–7.60 (m, 1H, Ar-H), 7.55 (t, *J* = 7.5 Hz, 2H, 2 × Ar-H), 7.38 (d, *J* = 7.1 Hz, 2H, 2 × Ar-H), 7.33–7.27 (m, 5H, 5 × Ar-H), 7.22 (t, *J* = 7.5 Hz, 1H, Ar-H), 7.15 (d, *J* = 7.1 Hz, 2H, 2 × Ar-H), 5.28 (ddd, ²J_(H-F) = 49.2 Hz, ³J_(H-H) = 8.7, 2.7 Hz, 1H, SCHFCH₂), 5.14 (d, ²J_(H-H) = 12.4 Hz, 1H, PhCHHO), 5.11 (d, ²J_(H-H) = 12.4 Hz, 1H, PhCHHO), 2.98–2.92 (m, 1H, PhCHHCH₂), 2.82–2.78 (m, 1H, PhCHHCH₂), 2.56–2.30 (m, 2H, 2 × CHHCHF); ¹³C NMR (125 MHz, CDCl₃) δ 164.9 (d, ⁴J_(C-F) = 1.7 Hz, CO₂N), 139.2 (2 × Ar-C_q), 137.3 (Ar-C_q), 133.5 (Ar-C), 129.9 (2 × Ar-C), 128.8 (2 × Ar-C), 128.6 (2 × Ar-C), 128.4 (2 × Ar-C), 128.3 (2 × Ar-C), 128.0 (2 × Ar-C), 127.9 (Ar-C), 126.7 (Ar-C), 105.3 (d, ¹J_(C-F) = 226.2 Hz, SCHF), 68.1 (OCH₂Ph), 32.3 (d, ²J_(C-F) = 18.7 Hz, CH₂CH₂CHF), 30.5 (d, ³J_(C-F) = 2.5 Hz, PhCH₂CH₂); ¹⁹F NMR (470 MHz, CDCl₃) δ -177.0 – -176.8 (m, 1F, CHF); HRMS (ESI) m/z Calcd for C₂₃H₂₂FNao₂S [M+Na]⁺ 418.1247; Found: 418.1262.



3bv-B; benzyl (1-fluoro-3-phenylpropyl)(phenyl)-I⁴-sulfanylidene carbamate


Prepared according to general procedure GP to afford **3bv-B** as a yellow oil (35 mg, 30%) after column chromatography (*R_f* = 0.2, hexane/Et₂O 6:4); IR (film)/cm⁻¹ 3063, 2921, 2851, 1634, 1446, 1376, 1244, 1086; ¹H

NMR (500 MHz, CDCl₃) δ 7.74 (d, J = 8.0 Hz, 2H, 2 \times Ar-H), 7.61–7.58 (m, 1 H, Ar-H), 7.54 (t, J = 7.5 Hz, 2H, 2 \times Ar-H), 7.40 (d, J = 7.2 Hz, 2H, 2 \times Ar-H), 7.34–7.26 (m, 5H, 5 \times Ar-H overlapping with CDCl₃), 7.21 (t, J = 7.2 Hz, 1H, Ar-H), 7.10 (d, J = 7.2 Hz, 2H, 2 \times Ar-H), 5.38 (ddd, $^2J_{(H-F)}$ = 46.8 Hz, $^3J_{(H-H)}$ = 9.6, 3.0 Hz, 1H, SCHFCH₂), 5.16 (d, $^2J_{(H-H)}$ = 12.5 Hz, 1H, PhCHHO), 5.13 (d, $^2J_{(H-H)}$ = 12.5 Hz, 1H, PhCHHO), 2.86–2.81 (m, 1H, PhCHHCH₂), 2.77–2.71 (m, 1H, PhCHHCH₂), 2.39–2.25 (m, 1H, CHHCHF), 1.99–1.89 (m, 1H, CHHCHF); ¹³C NMR (125 MHz, CDCl₃) δ 165.1 (CO₂N), 139.1 (2 \times Ar-C_q), 137.4 (Ar-C_q), 133.0 (Ar-C), 129.9 (2 \times Ar-C), 128.9 (2 \times Ar-C), 128.6 (2 \times Ar-C), 128.4 (4 \times Ar-C), 128.0 (2 \times Ar-C), 127.9 (Ar-C), 126.8 (Ar-C), 105.2 (d, $^1J_{(C-F)}$ = 230.6 Hz, SCHF), 68.2 (OCH₂Ph), 30.6 (d, $^3J_{(C-F)}$ = 3.0 Hz, PhCH₂CH₂), 30.5 (d, $^2J_{(C-F)}$ = 19.2 Hz, CH₂CH₂CHF); ¹⁹F NMR (470 MHz, CDCl₃) δ -179.0 – -178.8 (m, 1F, CHF); HRMS (ESI) m/z Calcd for C₂₃H₂₂FN₂O₂S [M+Na]⁺ 418.1247; Found: 418.1249.



3ca; 2-fluoro-1,1-diphenyldecan-1-ol


Prepared according to general procedure GP to afford **3ca** as a white waxy solid (191 mg, 97%) after column chromatography (R_f = 0.6, hexane/Et₂O 9:1); IR (film)/cm⁻¹ 3559, 3010, 2919, 2851, 1660, 1493, 1448, 1171; ¹H NMR (500 MHz, CDCl₃) δ 7.54 (d, J = 8.3 Hz, 2H, 2 \times Ar-H), 7.39–7.28 (m, 6H, 6 \times Ar-H), 7.24–7.20 (m, 2H, 2 \times Ar-H), 5.36 (ddd, $^2J_{(H-F)}$ = 47.0 Hz, $^3J_{(H-H)}$ = 10.0, 1.7 Hz, 1H, CHFCH₂), 2.60 (d, $^4J_{(H-F)}$ = 2.1, 1H, O-H), 1.82–1.78 (m, 1H, CHHCHF), 1.52–1.46 (m, 1H, CHHCH₂CHF), 1.37–1.21 (m, 12H, 5 \times CH₂ overlapping with CHHCHF and CHHCH₂CHF), 0.86 (t, J = 7.0 Hz, 3H, CH₃); ¹³C NMR (125 MHz, CDCl₃) δ 144.8 (Ar-C_q), 143.1 (d, $^3J_{(C-F)}$ = 4.1 Hz, Ar-C_q), 128.2 (4 \times Ar-C), 127.2 (Ar-C), 127.1 (Ar-C), 126.7 (d, $^4J_{(C-F)}$ = 1.6 Hz, 2 \times Ar-C), 125.8 (2 \times Ar-C), 96.3 (d, $^1J_{(C-F)}$ = 177.9 Hz, CHF), 79.1 (d, $^2J_{(C-F)}$ = 21.0 Hz, C_qOHCHF), 31.8 (CH₂), 29.4 (CH₂), 29.3 (CH₂), 29.2 (CH₂), 28.8 (d, $^2J_{(C-F)}$ = 21.3 Hz, CH₂CHF), 25.7 (d, $^3J_{(C-F)}$ = 2.9 Hz, CH₂CH₂CHF), 22.6 (CH₂), 14.1 (CH₃); ¹⁹F NMR (470 MHz, CDCl₃) δ -189.4 (ddd, $^2J_{(H-F)}$ = 47.0 Hz, $^3J_{(H-F)}$ = 42.7, 14.2 Hz, 1F, CHF); HRMS (ESI) m/z Calcd for C₂₂H₂₈FO [M-H]⁻ 327.2130; Found: 327.2127.



3ce; 1-(1-fluorononyl)-3-methylcyclohex-2-en-1-ol


Prepared according to general procedure GP to afford **3ce** as a white waxy solid (dr = 70:30, 104mg, 68%) after column chromatography (R_f = 0.3, hexane/Et₂O 8:2); *Inseparable mixture of diastereoisomers*; IR (film)/cm⁻¹ 3400, 2924, 2855, 1671, 1454, 1377, 1169, 1070, 967; ¹H NMR (500 MHz, CDCl₃, *mixture of diastereoisomers*) δ 5.41 (s, 0.4H *minor*, Csp²HCOH), 5.34 (s, 1H *major*, Csp²HCOH), 4.35–4.21 (m, 1H *major* + 0.4H *minor*, CHFCH₂), 1.99–1.80 (m, 3H *major* + 1.2H *minor*, CH₂ overlapping OH), 1.80–1.28 (m, 19H *major* + 7.6H *minor*), 0.88 (t, J = 6.9 Hz, 3H *major* + 1.2H *minor*, CH₃); ¹³C NMR (125 MHz, CDCl₃, *mixture of diastereoisomers*) δ 141.1 (d, $^4J_{(C-F)}$ = 1.0 Hz, Csp²CH₃), 140.8 (d, $^4J_{(C-F)}$ = 1.6 Hz, Csp²CH₃), 122.6 (d, $^3J_{(C-F)}$ = 4.5 Hz, Csp²COH), 122.4 (d, $^3J_{(C-F)}$ = 6.7 Hz, Csp²COH), 99.9 (d, $^1J_{(C-F)}$ = 174.0 Hz, CHF), 98.6 (d, $^1J_{(C-F)}$ = 174.8 Hz, CHF), 71.9 (d, $^2J_{(C-F)}$ = 20.2 Hz, C_qOHCHF), 71.6 (d, $^2J_{(C-F)}$ = 19.6 Hz, C_qOHCHF), 32.0 (2 \times CH₂), 31.4 (d, $^3J_{(C-F)}$ = 3.3 Hz, CH₂COH), 30.5 (d, $^3J_{(C-F)}$ = 3.3 Hz, CH₂COH), 30.5 (2 \times CH₂), 30.3 (2 \times CH₂), 29.7 (2 \times CH₂), 29.6 (2 \times CH₂), 29.3 (d, $^2J_{(C-F)}$ = 21.6 Hz, 2 \times CH₂CHF), 26.1 (d, $^3J_{(C-F)}$ = 2.4 Hz, CH₂CH₂CHF), 26.0 (d, $^3J_{(C-F)}$ = 2.8 Hz, CH₂CH₂CHF), 24.1 (2 \times CH₃Csp²) 22.8 (2 \times CH₂), 18.9 (2 \times CH₂), 18.6 (2 \times CH₂), 14.3 (2 \times CH₃); ¹⁹F NMR (470 MHz, CDCl₃, *mixture*

of diastereoisomers) δ -194.4 – -193.1 (m, 1F major, CHF), -196.2 (ddd, $^2J_{(H-F)} = 47.9$ Hz, $^3J_{(H-F)} = 42.4$, 15.2 Hz, 0.4F minor, CHF); HRMS (ESI) m/z Calcd for C₁₆H₂₉FNaO [M+Na]⁺ 279.2095; Found: 279.2106.



3cf; 1-(1-fluorononyl)cyclohexan-1-ol



Prepared according to general procedure GP to afford **3cf** as a white waxy solid (107 mg, 73%) after column chromatography ($R_f = 0.4$, hexane/EtOAc 95:5); IR (film)/cm⁻¹ 3436, 2987, 2956, 1450, 1378, 1258, 974, 905; ¹H NMR (500 MHz, CDCl₃) δ 4.26–4.14 (m, 1H, CHFCH₂), 1.71–1.62 (m, 5H, CHHCHF overlapping with CHHCH₂CHF, CHHCOH and CH₂), 1.58–1.48 (m, 1H, CHHCHF overlapping with O–H, CHHCOH, CHHCH₂CHF and 2 × CH₂), 1.41–1.19 (m, 12H, 2 × CHHCOH overlapping with 5 × CH₂), 0.88 (t, $J = 6.8$ Hz, 3H, CH₃); ¹³C NMR (125 MHz, CDCl₃) δ 99.8 (d, $^1J_{(C-F)} = 171.7$ Hz, CHF), 72.6 (d, $^2J_{(C-F)} = 19.5$ Hz, C_qOHCHF), 33.5 (d, $^3J_{(C-F)} = 4.2$ Hz, CH₂COH), 32.3 (d, $^3J_{(C-F)} = 3.7$ Hz, CH₂COH), 32.0 (CH₂), 29.7 (CH₂), 29.6 (CH₂), 29.4 (CH₂), 28.8 (d, $^2J_{(C-F)} = 21.7$ Hz, CH₂CHF), 26.0 (d, $^3J_{(C-F)} = 2.9$ Hz, CH₂CH₂CHF), 25.9 (CH₂), 22.8 (CH₂), 21.4 (2 × CH₂), 14.3 (CH₃); ¹⁹F NMR (470 MHz, CDCl₃) δ -189.4 (ddd, $^2J_{(H-F)} = 47.0$ Hz, $^3J_{(H-F)} = 42.7$, 14.2 Hz, 1F, CHF); HRMS (ESI) m/z Calcd for C₁₅H₂₉FNaO [M+Na]⁺ 267.2095; Found: 267.2079.









3ck; 1,1-dicyclopropyl-2-fluorodecan-1-ol



Prepared according to general procedure GP to afford **3ck** as (100 mg, 65%) after column chromatography ($R_f = 0.5$, hexane/Et₂O 9:1); IR (film)/cm⁻¹ 3494, 2925, 2855, 1465, 1378, 1023, 914, 827; ¹H NMR (500 MHz, CDCl₃) δ 4.36 (ddd, $^2J_{(H-F)} = 49.0$ Hz, $^3J_{(H-H)} = 10.4$, 2.2 Hz, 1H, CHFCH₂), 1.83–1.75 (m, 2H, CH₂), 1.71–1.56 (m, 2H, CHHCHF overlapping with, CHHCH₂CHF), 1.55 (s, 1H, O–H), 1.43–1.25 (m, 10H, CHHCHF overlapping with CHHCH₂CHF and 4 × CH₂), 0.92–0.86 (m, 4H, CH₃ overlapping with CHCOH), 0.79–0.73 (m, 1H, CHCOH), 0.49–0.29 (m, 8H, 4 × CH₂); ¹³C NMR (125 MHz, CDCl₃) δ 100.7 (d, $^1J_{(C-F)} = 174.6$ Hz, CHF), 71.9 (d, $^2J_{(C-F)} = 18.6$ Hz, C_qOHCHF), 32.0 (CH₂), 30.0 (d, $^2J_{(C-F)} = 21.4$ Hz, CH₂CHF), 29.7 (2 × CH₂), 29.4 (CH₂), 29.6 (CH₂), 29.4 (CH₂), 26.2 (d, $^3J_{(C-F)} = 2.6$ Hz, CH₂CH₂CHF), 22.8 (CH₂), 15.1 (d, $^3J_{(C-H)} = 4.7$ Hz, CHCOH), 14.6 (d, $^3J_{(C-H)} = 3.6$ Hz, CHCOH), 14.3 (CH₃), 0.8 (CH₂), 0.4 (d, $^4J_{(C-F)} = 0.8$ Hz, CH₂), -0.7 (CH₂), -0.9 (CH₂); ¹⁹F NMR (470 MHz, CDCl₃) δ -193.0 (ddd, $^2J_{(H-F)} = 49.0$ Hz, $^3J_{(H-F)} = 42.5$, 15.7 Hz, 1F, CHF); HRMS (ESI) m/z Calcd for C₁₆H₂₉FNaO [M+Na]⁺ 279.2095; Found: 279.2118.



5. Copy of ^1H , ^{13}C and ^{19}F NMR spectra for compounds 3aa-3ck




























3ag

Inseparable mixture of diastereoisomers

¹⁹F NMR


(470 MHz, CDCl₃)







3ah major



¹H NMR



(500 MHz, CDCl₃)














7.51
7.50
7.50
7.49
7.30
7.28
7.27
7.24
7.22
7.15
7.13
7.13
7.11
7.09
4.75
4.74
4.74
4.73
4.72
4.65
4.65
4.63
4.63
3.58
3.58
3.57
3.56
3.56
3.55
3.54
3.45
3.43
3.43
3.42
3.42
3.41
3.41
3.40
3.40
2.95
2.92
2.92
2.87
2.84
2.83
2.71
2.63
2.62
2.61
2.60
2.58
2.57
2.56
2.55
2.54
2.46
2.44
2.43
2.41




¹H NMR
(500 MHz, CDCl₃)







163.5
161.5
137.4
137.4
136.0
135.9
129.3
128.7
128.1
116.8
115.5
99.6
98.2
77.6
77.5
40.3
40.3
40.2
36.0
35.9






¹³C NMR
(125 MHz, CDCl₃)













3al

¹⁹F NMR
(470 MHz, CDCl₃)






7.28
7.28
7.27
7.26
7.23
7.22
7.21
7.20
7.17
7.16
7.04
7.03
7.03
7.02
7.02
7.01
7.01
4.77
4.76
4.75
4.74
4.67
4.67
4.65
2.99
2.96
2.94
2.93
2.91
2.85
2.82
2.77
2.74
2.42
2.42
1.75
1.75






3am-A

¹H NMR
(500 MHz, CDCl₃)













3am-B
¹⁹F NMR
 (470 MHz, CDCl₃)







7.33, 7.32, 7.32, 7.31, 7.30, 7.26, 7.23, 7.23, 4.61, 4.60, 4.60, 4.59, 4.59, 4.58, 4.51, 4.51, 4.50, 4.50, 4.49, 4.49, 3.59, 3.55, 3.06, 3.05, 3.04, 3.02, 3.01, 2.99, 2.98, 1.78, 1.76, 1.59, 1.58, 1.56, 1.55, 1.54, 1.54, 1.49, 1.48, 1.48, 1.46, 1.45, 1.37, 1.36, 1.35, 1.34, 1.33, 1.32, 1.32, 1.31, 1.29, 1.28, 1.28, 1.26, 0.89, 0.88, 0.87








3an-A
¹H NMR
 (500 MHz, CDCl₃)
































3as

¹⁹F NMR
(470 MHz, CDCl₃)




7.95
7.95
7.93
7.93
7.93
7.60
7.59
7.49
7.48
7.48
7.46
7.33
7.33
7.32
7.31
7.29
7.27
7.27
5.86
5.79
5.79
5.78
5.70
5.69
5.68
3.38
3.37
3.35
3.34
3.31
3.31
3.29
3.28
3.28
3.26
3.25
3.23
3.22
3.20




3at


¹H NMR
(500 MHz, CDCl₃)



7.33
7.31
7.30
7.27
7.27
7.26
7.24
7.23
7.22
4.97
4.96
4.95
4.87
4.87
4.86
4.85
3.23
3.22
3.20
3.19
3.17
3.16
3.14
3.13
3.08
3.07
3.05
3.04
3.03
3.01
3.00
2.99
2.48
2.48
2.47
2.46
2.45
2.44
2.44
2.43
2.27
2.26
2.25
2.25
2.23
2.23
2.22
2.21
2.14
2.13
2.12
2.10
2.09
0.91
0.89
0.86
0.84



3au
¹H NMR
(500 MHz, CDCl₃)




209.6
209.4

135.6
129.7
128.7
127.2


96.8
95.4



47.5
38.4
38.2



23.5
23.5
22.7
22.6






3au
¹³C NMR
(125 MHz, CDCl₃)













¹⁹F NMR
(470 MHz, CDCl₃)






7.31, 7.30, 7.28, 7.22, 7.20, 7.19, 4.45, 2.93, 2.92, 2.91, 2.90, 2.89, 2.88, 2.87, 2.85, 2.73, 2.72, 2.71, 2.70, 2.69, 2.68, 2.66, 2.09, 2.08, 2.07, 2.06, 2.05, 2.04, 1.90, 1.88, 1.87, 1.85, 1.84, 1.83, 1.82, 1.80, 1.72, 1.56, 1.48, 1.47, 1.47, 1.46, 1.45, 1.44, 1.43, 1.42, 1.41, 1.40, 1.28, 1.26, 0.89, 0.88, 0.87




3bn
Inseparable mixture of diastereoisomers

¹H NMR
(500 MHz, CDCl₃)












3bo

Inseparable mixture of diastereoisomers

¹⁹F NMR
(470 MHz, CDCl₃)






1.0H
1.0H







3bt



¹H NMR
(500 MHz, CDCl₃)
















3ca


^{19}F NMR
(470 MHz, CDCl_3)







3ce


Inseparable mixture of diastereoisomers

^1H NMR
(500 MHz, CDCl_3)











3cf

¹⁹F NMR
(470 MHz, CDCl₃)






4.42
4.40
4.39
4.32
4.32
4.30
4.29
1.80
1.78
1.55
1.43
1.42
1.42
1.37
1.35
1.34
1.31
1.29
1.29
1.28
1.25
0.90
0.89
0.88
0.87
0.86
0.77
0.76
0.75
0.74
0.49
0.49
0.48
0.48
0.47
0.47
0.47
0.46
0.46
0.45
0.44
0.43
0.42
0.42
0.41
0.40
0.40
0.39
0.37
0.36
0.35
0.35
0.34
0.34
0.32
0.31



3ck

¹H NMR
(500 MHz, CDCl₃)





6. References

- 1 A. F. Burchat, J. M. Chong and N. Nielsen, *J. Organomet. Chem.*, 1997, **542**, 281.
- 2 X. Jiang, S. Sakthivel, K. Kulbitski, G. Nisnevich and M. Gandelman, 2014, 8.
- 3 W. Li, A. Varenikov and M. Gandelman, *European J. Org. Chem.*, 2020, **2020**, 3138.
- 4 X. Jiang and M. Gandelman, *J. Am. Chem. Soc.*, 2015, **137**, 2542.
- 5 W. R. Dolbier and M. Okamoto, *J. Fluor. Chem.*, 2015, **179**, 33.
- 6 M. Andresini, M. Spennacchio, M. Colella, G. Losito, A. Aramini, L. Degennaro and R. Luisi, *Org. Lett.*, 2021, **23**, 6850.
- 7 H. Bao, L. Bayeh and U. K. Tambar, *Angew. Chem. Int. Ed.*, 2014, **53**, 1664.
- 8 J. Morvan, T. McBride, I. Curbet, S. Colombel-Rouen, T. Roisnel, C. Crévisy, D. L. Browne and M. Mauduit, *Angew. Chem. Int. Ed.*, 2021, **60**, 19685.
- 9 G. Landelle, M.-O. Turcotte-Savard, L. Angers and J.-F. Paquin, *Org. Lett.*, 2011, **13**, 1568.
- 10 T. B. Patrick, L. Zhang and Q. Li, *J. Fluor. Chem.*, 2000, **102**, 11.
- 11 S. Ponra, J. Yang, S. Kerdphon and P. G. Andersson, *Angew. Chemie Int. Ed.*, 2019, **58**, 9282.